Bristol Myers Squibb - All News

U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)

Fri, 20 Nov 2009 23:50:00 UT

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changi

Bristol-Myers Squibb Announces Split-Off of Mead Johnson

Mon, 16 Nov 2009 00:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced it will split off its holdings in Mead Johnson Nutrition Company. The company expects the split-off to be a tax-advantaged way to further deliver value to Bristol-Myers Squibb shareholders. The split-off is expected to be net cash flow positive to the BioPharma business and accretive to earnings per share beginning in 2010. “This marks the latest step in our company’s transformation into a BioPharma l

Bristol-Myers Squibb to Present at Credit Suisse Healthcare Conference

Tue, 10 Nov 2009 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at a Credit Suisse healthcare conference on Thursday, November 12, 2009 in Phoenix, Arizona. Jean-Marc Huet, executive vice president and chief financial officer of Bristol-Myers Squibb, will make a formal presentation about the company at 10:30 a.m. ET. Investors and the general public are invited to listen to a live webcast of the presentation at http://investor.bms.com. Materials related to the presentation will b

Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic

Tue, 10 Nov 2009 12:00:00 UT

PRINCETON, N.J. & BOTHELL, Wash.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals, Inc., today announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis. Under the terms of the collaboration agreement, Alder will grant to Bristol-Myers Squibb worldwide exclusive rights to develop and commercialize ALD518 for all potential indications ex

FDA Approves Labeling Update for REYATAZ® (atazanavir sulfate) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients

Thu, 5 Nov 2009 23:09:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for REYATAZ® to include long-term data from the CASTLE Study. The CASTLE Study assessed a once-daily REYATAZ/ritonavir (REYATAZ/r)-based regimen versus a twice-daily lopinavir/ritonavir (LPV/r)-based regimen in previously untreated adult patients infected with HIV-1. Data from the study demonstrate enduring virologic respo

BARACLUDE® (entecavir) Demonstrated Greater Antiviral Efficacy Compared to Adefovir in New Study of Chronic Hepatitis B Patients with Evidence of Decompensated Cirrhosis

Sat, 31 Oct 2009 21:31:00 UT

BOSTON--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases. Decompensated cirrhosis is characterized by severe scarring of the liver caused by chronic liver inflammati

Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C

Sat, 31 Oct 2009 21:30:00 UT

PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients. The poster included data on 56 patients in the study. Antiviral activity was observed at all dose levels tested. The results will be presented at the American Association for the Study of the

Bristol-Myers Squibb Donation to Benefit Students at The Pennington School and Beyond

Thu, 29 Oct 2009 13:00:00 UT

PENNINGTON, N.J.--(BUSINESS WIRE)--Students at The Pennington School will have an unprecedented opportunity this year to conduct hands-on, high-tech science projects, thanks to sophisticated science equipment donated by Bristol-Myers Squibb Company (NYSE: BMY). The instrument – an atomic absorption spectrometer – measures the amounts of different chemical elements present in a particular substance. Bristol-Myers Squibb, which uses such equipment in research and development, arranged

Medarex, Inc. Announces Expiration of Offer to Repurchase its 2.25% Convertible Senior Notes due May 15, 2011

Mon, 26 Oct 2009 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Medarex, Inc., a wholly owned subsidiary of Bristol-Myers Squibb Company (NYSE: BMY), announced today that its offer to repurchase its 2.25% Convertible Senior Notes due May 15, 2011 (the “Convertible Notes”) expired on October 23, 2009 pursuant to terms of the notice of change in control to holders of the Convertible Notes dated September 23, 2009. The trustee for the Convertible Notes has advised Medarex that no Convertible Notes were tendered in the offe

Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer

Fri, 23 Oct 2009 22:40:00 UT

SOUTH SAN FRANCISCO, Calif. & NEW YORK--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. The data from study XL184-201 were presented today during a poster session at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors. The study

Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter

Thu, 22 Oct 2009 11:30:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reported strong sales and earnings growth for the third quarter 2009. “The performance in the third quarter of 2009 clearly shows the results of our outstanding business performance, disciplined financial management and overall strategic execution,” said James M. Cornelius, chairman and chief executive officer. “We are transforming Bristol-Myers Squibb into a BioPharma leader and the recent approval and la

New Data Describe Safety of Subcutaneous Administration of ORENCIA® (abatacept) For Patients with Moderate to Severe Rheumatoid Arthritis

Tue, 20 Oct 2009 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that new clinical data support continued development of a subcutaneous administration of ORENCIA® (abatacept) for patients with moderate to severe rheumatoid arthritis. Bristol Myers-Squibb has a comprehensive development program underway to evaluate the potential subcutaneous administration of ORENCIA through an injection into the skin in adults with moderate to severe rheumatoid arthritis. ORENCIA is alread

ORENCIA® (abatacept) Demonstrated Sustained Clinical Response in a Study of Adult Patients with Moderate to Severe Early Rheumatoid Arthritis (Less Than Two Years Duration)

Mon, 19 Oct 2009 00:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced two-year results of a study that supports use of ORENCIA® (abatacept) for methotrexate-naive patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration. The data from the AGREE study, which compared patients treated with ORENCIA plus methotrexate versus patients treated with methotrexate alone, show that patients taking ORENCIA in combination with methotrexate achieved s

ONGLYZA™ (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes

Mon, 5 Oct 2009 20:15:00 UT

PARIS & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE/LSE: AZN) announced today that the European Commission has granted marketing authorisation for ONGLYZATM in the 27 countries of the European Union. ONGLYZA is indicated as a once-daily 5 mg oral tablet dose in adult patients with type 2 diabetes mellitus to improve glycaemic control: in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic contro

Study Finds That ONGLYZA™ (saxagliptin) When Added To Metformin Was Non-Inferior To JANUVIA (SITAGLIPTIN) When Added To Metformin In Reducing Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus

Mon, 5 Oct 2009 13:39:00 UT

PRINCETON, N.J. and LONDON--(BUSINESS WIRE)--Results from an 18-week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA™ (saxagliptin) 5 mg per day achieved the primary objective of demonstrating non-inferiority compared to the addition of treatment with JANUVIA® (sitagliptin) 100 mg per day in reducing HbA1c from baseline. In this study, overall adverse events were reported at a s

Bristol-Myers Squibb to Announce Results for the Third Quarter of 2009 on October 22

Fri, 2 Oct 2009 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2009 on Thursday, October 22. During a 10:30 a.m. (ET) conference call on October 22, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by dialing 913-312-1296, confirmation code: 4883550. Materials related to th

Dapagliflozin Study Demonstrated Significantly Improved Glycemic Control and Weight Reduction in Type 2 Diabetes Patients Inadequately Controlled with Metformin

Fri, 2 Oct 2009 09:01:00 UT

VIENNA--(BUSINESS WIRE)--Results from a 24-week phase 3 clinical study demonstrated that the investigational drug dapagliflozin, added to metformin, demonstrated significant mean reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c) and in the secondary endpoint, fasting plasma glucose (FPG) in patients with type 2 diabetes inadequately controlled with metformin alone, as compared to placebo plus metformin. Dapagliflozin is a novel, selective, sodium glucose co-transporter 2

Bristol-Myers Squibb and ZymoGenetics to Present Final Phase Ib Data on PEG-Interferon Lambda at AASLD 2009

Thu, 1 Oct 2009 14:45:00 UT

PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston. “Bristol-Myers Squibb is pleased to pa

New Data on Four Bristol-Myers Squibb Compounds to Be Presented at AASLD 2009

Thu, 1 Oct 2009 14:38:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--New data on four Bristol-Myers Squibb Company (NYSE:BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3. Data will be presented on BARACLUDE® (entecavir) in patients with chronic hepatitis B, and on two compounds in early clinical development for the treatment of hepatitis C -- BMS-650032, an NS3 inhibitor, and PEG-Interferon lambda, a novel t

Medarex, Inc. Issues Notice of Change in Control to Holders of its Convertible Notes

Thu, 24 Sep 2009 18:41:00 UT

NEW YORK--(BUSINESS WIRE)--Medarex, Inc., a wholly owned subsidiary of Bristol-Myers Squibb Company (NYSE: BMY), issued, under the terms of the indenture for Medarex’s 2.25% Convertible Senior Notes due May 15, 2011 (the “Convertible Notes”), a notice of change in control (the “Company Notice”) to holders of the Convertible Notes. The change in control of Medarex resulted from the expiration of the initial offering period and acceptance on August 27, 2009 by Puma Ac

Data Presented from Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress

Wed, 23 Sep 2009 12:15:00 UT

BERLIN--(BUSINESS WIRE)--According to a recent retrospective analysis of the pivotal Phase 3 CRYSTAL study, ERBITUX® (cetuximab), when added to FOLFIRI, was shown to increase median overall survival to 19.9 months in an intent-to-treat (ITT) population of first-line metastatic colorectal cancer (mCRC) patients compared to 18.6 months in those receiving FOLFIRI alone (hazard ratio [HR] 0.878; 95% CI 0.774 – 0.995; p=0.042). In a subset of mCRC patients with wild-type K-ras tumors, medi

Bristol-Myers Squibb Company Announces Sale to Taisho Pharmaceutical Co Ltd., of Its OTC Assets in Asia Pacific (Excl. China & Japan) and Shares in PT Bristol-Myers Squibb Indonesia Tbk

Wed, 16 Sep 2009 03:00:00 UT

JAKARTA, Indonesia--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has reached an agreement for the sale of its OTC assets in Asia Pacific (excluding China and Japan) to Taisho Pharmaceutical Co., Ltd. (“Taisho”). Pursuant to the terms of the definitive agreement, Taisho will acquire from Bristol-Myers Squibb certain product registrations, trademarks and related assets of selected pharmaceutical and over-the-counter products sold primarily in Indone

Bristol-Myers Squibb to Present at Morgan Stanley Global Healthcare Unplugged Conference

Fri, 11 Sep 2009 13:45:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September 14, 2009 in New York. Lamberto Andreotti, president and chief operating officer of Bristol-Myers Squibb, will make a presentation on the company at 2:10 p.m. ET on September 14. Investors and the general public are invited to listen to a live webcast of the presentation at http://investor.bms.com. An archived edition of the presentation

Bristol-Myers Squibb Announces Dividend

Wed, 9 Sep 2009 20:05:00 UT

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE: BMY) declared a quarterly dividend of thirty-one cents ($0.31) per share on the $.10 par value Common Stock of the corporation. The quarterly dividend will be payable on November 2, 2009 to stockholders of record at the close of business on October 2, 2009. The Directors also declared a quarterly dividend of fifty cents ($0.50) per share on the $2.00 Convertible Preferred Stock of the corporation, payable De

Bristol-Myers Squibb Announces Acceptance of Submission for Belatacept Biologic License Application

Thu, 3 Sep 2009 21:03:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the company’s submission of a biologic license application for belatacept, which is in ongoing phase III development for use in kidney transplantation. The Prescription Drug User Fee Act (PDUFA) goal date for the FDA is May 1, 2010. “Belatacept has the potential to address significant unmet medical needs of transplant

Bristol-Myers Squibb Completes Acquisition of Medarex, Inc.

Tue, 1 Sep 2009 21:11:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has completed its previously announced $2.4 billion acquisition of Medarex, Inc. (NASDAQ: MEDX) (“Medarex”). As a result of the transaction, Medarex has become a wholly-owned subsidiary of Bristol-Myers Squibb. Bristol-Myers Squibb initiated on July 28, 2009 a cash tender offer to purchase all outstanding shares of common stock of Medarex for $16.00 per share. The tender offer period expired a

Bristol-Myers Squibb Completes Tender Offer for Medarex, Inc.

Tue, 1 Sep 2009 12:10:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the depositary for its tender offer for all the outstanding common stock of Medarex has advised that, as of the expiration of the subsequent offering period, shareholders of Medarex, Inc. (NASDAQ: MEDX) (“Medarex”) tendered approximately 120,417,467 shares, representing, together with the 2,879,223 shares of Medarex common stock owned by Bristol-Myers Squibb since January 2005, approximately 90.7

New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of Plavix® in Acute Coronary Syndrome Patients Undergoing Angioplasty

Sun, 30 Aug 2009 06:00:00 UT

PARIS & PRINCETON, N.J.--(BUSINESS WIRE)--Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sanofi-aventis (EURONEXT: SAN, and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY), co-commercialization and co-development partners for PLAVIX® (clopidogrel bisulfate), were sponsors of the study. CURRENT-OASIS 7 is the largest clinical trial (25,087 patients) to evaluate different dosi

Bristol-Myers Squibb Completes Initial Tender Offer for Medarex, Inc. with 87.7% of Shares Tendered; Announces Subsequent Offering Period

Thu, 27 Aug 2009 12:10:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the initial tender offer, through its wholly owned subsidiary, Puma Acquisition Corporation, for all outstanding shares of common stock of Medarex, Inc. (NASDAQ: MEDX) (“Medarex”) expired at midnight (New York City time) on August 26, 2009, and was not extended. The depositary for the tender offer has advised Bristol-Myers Squibb that, as of the expiration of the initial tender offer, shareholder

Updated ORENCIA® (abatacept) Labeling Includes Data to Support Earlier Use in Adult Patients with Moderate to Severe Rheumatoid Arthritis

Wed, 26 Aug 2009 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that clinical data added to the labeling for ORENCIA® (abatacept) support use of ORENCIA for patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration. ORENCIA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely activ

Bristol-Myers Squibb Extends Tender Offer for Medarex, Inc.

Thu, 20 Aug 2009 20:53:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has extended its previously announced cash tender offer, through its wholly-owned subsidiary, Puma Acquisition Corporation, to

Bristol-Myers Squibb Announces Preliminary Court Approval of Derivative Settlement

Thu, 20 Aug 2009 13:10:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the United States District Court for the Southern District of New York has granted preliminary approval of settlement of Sampson

Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of Medarex, Inc.

Wed, 12 Aug 2009 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex, Inc. (NASDAQ: MEDX) has expired.

U.S. Food and Drug Administration Approves ONGLYZA™ (saxagliptin) for the Treatment of Type 2 Diabetes Mellitus in Adults

Fri, 31 Jul 2009 23:18:00 UT

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved ONGLYZA™ (saxagliptin), a

Bristol-Myers Squibb Begins Tender Offer to Acquire Medarex, Inc.

Tue, 28 Jul 2009 09:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) is commencing today, through its wholly owned subsidiary Puma Acquisition Corporation, a cash tender offer to purchase all outstanding shares of common

Excellent Performance Highlights Second Quarter for Bristol-Myers Squibb

Thu, 23 Jul 2009 11:30:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reported sales and earnings growth for the second quarter 2009.

Bristol-Myers Squibb to Acquire Medarex

Wed, 22 Jul 2009 23:16:00 UT

NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Medarex, Inc. (NASDAQ: MEDX) announced today that the companies have signed a definitive merger agreement providing for the

ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX® (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer

Mon, 20 Jul 2009 11:30:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY), and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA)

Bristol-Myers Squibb’s SECURE THE FUTURE Announces $1.3 Million in New Grants to Enhance Community-Based HIV/AIDS Care and Support in Africa

Mon, 20 Jul 2009 08:00:00 UT

CAPE TOWN, South Africa--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and the Bristol-Myers Squibb Foundation today announced new grants providing technical assistance and $1.3 million in funding to

Bristol-Myers Squibb to Announce Results for the Second Quarter and First Six Months of 2009 on July 23

Thu, 9 Jul 2009 20:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter and first six months of 2009 on Thursday, July 23. During a 10:30 a.m. (ET) conference call, company

New Online Resource Launches For Patients With Chronic Myeloid Leukemia

Mon, 6 Jul 2009 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Many people living with cancer are researching their illnesses online. In fact, research has shown that patients who use the Internet consider it a more useful source of information as

ONGLYZA™ (Saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes

Thu, 25 Jun 2009 16:04:00 UT

PARIS & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that their marketing authorization application for ONGLYZA™ (saxagliptin) received a positive

ORENCIA® (abatacept) Demonstrates Consistent Safety and Effectiveness Over 7 Years

Fri, 12 Jun 2009 07:00:00 UT

COPENHAGEN--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results of two ORENCIA® (abatacept) studies at the 2009 Annual European Congress of Rheumatology (EULAR) currently being held

Bristol-Myers Squibb Announces Dividend

Wed, 10 Jun 2009 20:00:00 UT

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-one cents ($0.31) per share on the $.10 par value Common Stock of the

Bristol-Myers Squibb to Present at Goldman Sachs Global Healthcare Conference

Wed, 10 Jun 2009 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2009 in New York. Elliott Sigal, M.D., Ph.D., executive vice

Interim Analysis of Long-Term Data with ONGLYZA™ (saxagliptin) When Added to Metformin in People with Inadequately Controlled Type 2 Diabetes Presented at ADA Annual Scientific Sessions

Sat, 6 Jun 2009 15:00:00 UT

PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)--Results from an interim analysis of a long-term Phase 3 study at 102 weeks with ONGLYZA™ (saxagliptin), an investigational, selective, reversible inhibitor of

Dapagliflozin Study Demonstrated Improved Glycemic Control In Type 2 Diabetes Patients Treated With High Doses of Insulin and Common Oral Anti-Diabetic Medicines

Sat, 6 Jun 2009 15:00:00 UT

PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)--Results from a 12-week study demonstrated that the investigational drug dapagliflozin, a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor,

Exelixis and BMS Report Phase 2 Data to Be Presented at ASCO for XL184 in Patients with Previously Treated Glioblastoma Multiforme

Sun, 31 May 2009 13:05:00 UT

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported encouraging data from an ongoing phase 2 trial of XL184 in

Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg)

Sun, 31 May 2009 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) today announced updated survival results from follow-up extensions of three Phase 2 ipilimumab studies of

First Phase III Data on Innovative Compound for Solid Organ Transplantation To be Featured at American Transplant Congress

Thu, 28 May 2009 18:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that belatacept, an investigational co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of

FDA Grants Full Approval for SPRYCEL® (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec®*

Tue, 26 May 2009 19:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for SPRYCEL® (dasatinib) for the treatment of adults

Bristol-Myers Squibb to Present at Bernstein Strategic Decisions Conference

Tue, 26 May 2009 17:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bernstein Strategic Decisions Conference on Wednesday, May 27, 2009 in New York. Jim Cornelius, chairman and chief executive

Phase I Testing to Commence on Second Compound Developed from AMRI, Bristol-Myers Squibb Collaboration

Tue, 26 May 2009 12:00:00 UT

ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ: AMRI) announced today that Bristol-Myers Squibb Company (NYSE: BMY) has submitted a Clinical Trial Application (CTA) to the Medical Products Agency (MPA) in Sweden for

Bristol-Myers Squibb Welcomes “Help is Here Express” to New Brunswick

Fri, 22 May 2009 14:56:00 UT

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--With New Jersey’s unemployment rate hovering around 8.3 percent, thousands of residents are facing the loss of health insurance. Many, however, may be eligible for patient

Bristol-Myers Squibb to Present at Deutsche Bank Healthcare Conference

Mon, 18 May 2009 19:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Deutsche Bank Healthcare Conference on Tuesday, May 19, 2009 in Boston. Jean-Marc Huet, executive vice president and chief

SPRYCEL® (Dasatinib) Shows Potential as Treatment for Prostate Cancer

Thu, 14 May 2009 22:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced interim results from two Phase II studies of SPRYCEL® (dasatinib) which demonstrate that the medicine may have potential as a

Bristol-Myers Squibb to Present at Bank of America and Merrill Lynch Health Care Conference

Tue, 12 May 2009 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bank of America and Merrill Lynch Health Care Conference on Wednesday, May 13, 2009 in New York. Lamberto Andreotti, president and

Bristol-Myers Squibb to Present at Bernstein Pharmaceutical Emerging Markets Conference

Tue, 5 May 2009 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will present at the Bernstein Pharmaceutical Emerging Markets Conference on Wednesday, May 6, 2009. John Celentano, president of Emerging Markets and

Bristol-Myers Squibb Invites Public to Listen to Webcast of 2009 Annual Meeting

Wed, 29 Apr 2009 14:30:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) invites investors and the general public to listen to a webcast of its annual meeting with stockholders at 9:45 a.m. ET on Tuesday, May 5, 2009. In

Bristol-Myers Squibb Reports Excellent First Quarter Financial Results; Delivers on Two Significant Strategic Initiatives

Tue, 28 Apr 2009 11:30:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced first quarter results which included excellent financial performance and successful execution of two key strategic initiatives. The

Bristol-Myers Squibb Announces Call for Entries for the 2009 REYATAZ® (atazanavir sulfate) “Fight HIV Your Way” Contest

Mon, 27 Apr 2009 15:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced the call for entries for the REYATAZ® (atazanavir sulfate) “Fight HIV Your Way” Contest for photographs with

Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C

Fri, 24 Apr 2009 10:00:00 UT

PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today reported that the administration of the investigational compound PEG-Interferon lambda in

U.S. Food and Drug Administration Extends Review Timeline for ONGLYZA™ (saxagliptin) New Drug Application

Thu, 23 Apr 2009 12:00:00 UT

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) reported today that the U.S. Food and Drug Administration (FDA) has determined it needs additional time to

Bristol-Myers Squibb to Announce Results for the First Quarter of 2009 on April 28

Mon, 20 Apr 2009 20:09:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2009 on Tuesday, April 28. During an 11 a.m. (ET) conference call on April 28, company executives will

Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY® and Establishment of an Oncology Collaboration with Otsuka

Mon, 6 Apr 2009 08:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced an agreement with Otsuka Pharmaceutical Co., Ltd. (hereafter, “Otsuka”) to extend the U.S. portion of the

ONGLYZA™ (saxagliptin) Cardiovascular Profile Acceptable According to FDA Advisory Committee

Wed, 1 Apr 2009 22:19:00 UT

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs

Plavix(®) Plus Aspirin More Effective Than Aspirin Alone in Preventing Major Vascular Events in Patients with Atrial Fibrillation Who Cannot Take Oral Anticoagulants

Tue, 31 Mar 2009 13:23:00 UT

PARIS & PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today new findings from a landmark investigational study that demonstrated

Dapagliflozin Clinical Trial Results Indicate Improvement In Key Glycemic Measures In Treatment-Naïve Type 2 Diabetes Patients

Fri, 27 Mar 2009 14:00:00 UT

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Findings published today in Diabetes Care from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a novel, selective, sodium glucose co-transporter2 (SGLT2)

Bristol-Myers Squibb to Present at Healthcare Conference

Mon, 16 Mar 2009 19:46:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17, 2009 in Boston. Brian Daniels, senior vice president,

Bristol-Myers Squibb to Present at Healthcare Conference

Mon, 9 Mar 2009 20:50:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Barclay’s Capital Global Healthcare Conference on Tuesday, March 10, 2009 in Miami Beach, FL. Jean-Marc Huet, executive vice

Bristol-Myers Squibb Enters Global Collaboration with Nissan Chemical and Teijin Pharma on Novel Atrial Fibrillation Compound

Thu, 5 Mar 2009 01:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced a global collaboration with Nissan Chemical Industries, Ltd. and Teijin Pharma Limited for the development and

Bristol-Myers Squibb Announces Dividend

Tue, 3 Mar 2009 22:00:00 UT

Bristol-Myers Squibb Announces Organizational Changes; Names Four to Company’s Executive Committee

Tue, 3 Mar 2009 21:07:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced a series of related organizational changes consistent with the company’s transformation to a next-generation BioPharma leader.

Bristol-Myers Squibb Names Andreotti President and Chief Operating Officer

Tue, 3 Mar 2009 21:01:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb Company (NYSE: BMY) today announced that Lamberto Andreotti, 58, has been elected president and chief operating officer, and a member of the company’s Board of

ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX® in U.S.

Mon, 2 Mar 2009 15:45:00 UT

Bristol-Myers Squibb Foundation Announces Funding of More Than $1.17 Million to Bridge Gaps in Hepatitis C Awareness, Prevention and Care in China, India and Taiwan

Fri, 13 Feb 2009 05:01:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--The Bristol-Myers Squibb Foundation today announced funding of more than $1.17 million, focused on hepatitis C prevention and education and the mitigation of the disease in China,

Bristol-Myers Squibb Statement on Mead Johnson Nutrition Company IPO

Wed, 11 Feb 2009 15:06:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) issued the following statement on today’s initial public offering of Mead Johnson Nutrition Company (NYSE:MJN):

Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb

Tue, 27 Jan 2009 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY):

ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX®

Fri, 23 Jan 2009 20:29:00 UT

Bristol-Myers Squibb To Announce Results For The Fourth Quarter And Full Year Of 2008 On January 27

Fri, 16 Jan 2009 14:20:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter and full year of 2008 on Tuesday, January 27. During a 10:30 a.m. (ET) conference call on January 27,

Bristol-Myers Squibb to Present at Healthcare Conference

Tue, 13 Jan 2009 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at a J.P. Morgan healthcare conference on Wednesday, January 14, 2009 in San Francisco. Elliott Sigal, M.D., Ph.D., executive vice

Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C Compound

Mon, 12 Jan 2009 21:00:00 UT

PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (Nasdaq: ZGEN) today announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon

Howard Feldman Joins Bristol-Myers Squibb as Vice President and Therapeutic Area Head, Global Clinical Research, Neuroscience

Thu, 8 Jan 2009 14:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that Dr. Howard Feldman has joined the company's Research and Development organization as vice president and therapeutic area

Bristol-Myers Squibb Announces Dividend

Thu, 18 Dec 2008 22:15:00 UT

Exelixis And Bristol-Myers Squibb Sign New Collaboration Agreement To Develop Novel Cardiovascular Disease Treatments Focus on LXR-Targeted Therapies for Atherosclerosis and Coronary Artery Disease

Tue, 16 Dec 2008 02:39:00 UT

SOUTH SAN FRANCISCO, Calif. & NEW YORK--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a collaboration agreement to discover, develop and commercialize novel

New Data Demonstrate Significant Improvement in Progression-Free Survival for Triple Negative Metastatic Breast Cancer Patients Treated with IXEMPRA™ Plus Capecitabine

Fri, 12 Dec 2008 23:00:00 UT

SAN ANTONIO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced new data from studies of IXEMPRA™ (ixabepilone) plus capecitabine compared to capectabine alone, including a pre-specified sub

Sanofi-Aventis and Bristol-Myers Squibb Prevail before the U.S. Court of Appeals for the Federal Circuit in the U.S Plavix® Patent Infringement Case

Fri, 12 Dec 2008 17:30:00 UT

PARIS & NEW YORK--(BUSINESS WIRE)--Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb (New York: NYSE: BMY) announced today that the U.S. Court of Appeals for the Federal

New Jersey Youth Get Rapid Access to Mental Health Services

Fri, 12 Dec 2008 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Children and adolescents from low-income households who need mental health care in New Jersey often face delays of weeks or even months for treatment. Now, a new program by a state

Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs

Fri, 12 Dec 2008 10:54:00 UT

PRINCETON, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Exelixis, Inc. (Nasdaq: EXEL) today announced a global collaboration covering two novel molecules for cancer

Bristol-Myers Squibb to Announce 2003 Fourth Quarter and Full Year Earnings On January 29, 2004

Thu, 11 Dec 2008 19:10:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce 2003 fourth quarter and full year earnings on Thursday, January 29. During a conference call on that day at 10:30 a.m. (ET), financial

ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration

Mon, 8 Dec 2008 15:05:00 UT

Bristol-Myers Squibb and AstraZeneca Announce Expansion of Worldwide Collaboration to Develop and Commercialize Dapagliflozin in Japan

Mon, 8 Dec 2008 12:30:00 UT

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced expansion of their worldwide collaboration to include the development and

New Television Campaign in Mandarin to Educate Chinese Americans about Chronic Hepatitis B

Thu, 4 Dec 2008 16:20:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Today, Bristol-Myers Squibb Company (NYSE: BMY) announced the launch of its first-ever, non-English-language television campaign in the United States. The campaign, exclusively in

Bristol-Myers Squibb to Present at Healthcare Conference

Thu, 13 Nov 2008 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--

Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal

Thu, 6 Nov 2008 07:00:00 UT

PARIS AND PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis (NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the American Heart Journal published the

New Data Suggest Long-Term Treatment with BARACLUDE(R) (entecavir) May Reduce Liver Damage Caused by Chronic Hepatitis B

Sun, 2 Nov 2008 16:00:00 UT

SAN FRANCISCO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced data from two separate cohort evaluations, in which long-term treatment with BARACLUDE

Bristol-Myers Squibb Foundation to Award $1.4 Million in Grants to Bridge Gaps in Hepatitis C Awareness, Prevention and Care in Asia

Fri, 31 Oct 2008 14:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--

ERBITUX(R) Supplemental Biologics License Application for First-Line Recurrent or Metastatic Head and Neck Cancer Accepted for Priority Review by U.S. Food and Drug Administration

Thu, 30 Oct 2008 20:55:00 UT

NEW YORK--(BUSINESS WIRE)--

Use of Investigational Agent Entecavir Demonstrated Statistically Significant Improvement in Liver Histology and Viral Suppression Compared to Lamivudine in Chronically Infected Hepatitis B E-Antigen (HBeAg) Positive Patients

Wed, 29 Oct 2008 12:00:00 UT

BOSTON--(BUSINESS WIRE)--Data to be presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) demonstrated that treatment with the Bristol-Myers Squibb Company (NYSE: BMY)

Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Children With Juvenile Idiopathic Arthritis

Tue, 28 Oct 2008 00:39:00 UT

SAN FRANCISCO--(BUSINESS WIRE)--

Study Results Demonstrate More Patients With Early Erosive Rheumatoid Arthritis Treated With ORENCIA(R) (abatacept) and Methotrexate (MTX) Achieved DAS28 (CRP)-Defined Remission Compared to MTX Alone

Mon, 27 Oct 2008 22:45:00 UT

SAN FRANCISCO--(BUSINESS WIRE)--

96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/Ritonavir and Twice-Daily Lopinavir/Ritonavir In Previously Untreated HIV-1 Infected Adult Patients

Sun, 26 Oct 2008 16:30:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week data from the CASTLE study, in which 74 percent of the 440 patients in the REYATAZ

Bristol-Myers Squibb Continues Excellent Financial Performance Led By Double-Digit Global Net Sales Growth and Strong Earnings Results

Thu, 23 Oct 2008 11:30:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY):

Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment

Wed, 22 Oct 2008 21:00:00 UT

NEW YORK--(BUSINESS WIRE)--

Bristol-Myers Squibb to Announce Results for the Third Quarter of 2008 on October 23

Tue, 14 Oct 2008 20:15:00 UT

NEW YORK--(BUSINESS WIRE)--

Introducing Pediatric Care Online(TM)

Fri, 10 Oct 2008 14:30:00 UT

BOSTON--(BUSINESS WIRE)--The American Academy of Pediatrics (AAP) is introducing a revolutionary, next-generation point-of-practice resource to the nation’s

Bristol-Myers Squibb and Capital Health System to Host Health Fair and Visits by Hollywood Star Joey Pantoliano and 'Help Is Here Express' Bus to Raise Awareness about Chronic Diseases and Prescription Drug Assistance

Fri, 10 Oct 2008 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--On Tuesday, October 14, Bristol-Myers Squibb Company (NYSE: BMY) and Capital Health System will host a community health fair to raise awareness about the

Bristol-Myers Squibb Comments on Eli Lilly as New Erbitux Marketing Partner

Mon, 6 Oct 2008 15:41:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) announced today that it will acquire ImClone Systems (NASDAQ:IMCL) for $70 per share, or approximately $6.5 billion.

BIPAI Opens New Children's AIDS Center in Uganda

Thu, 2 Oct 2008 14:00:00 UT

HOUSTON--(BUSINESS WIRE)--The Baylor International Pediatric AIDS Initiative today opened a state-of-the-art HIV/AIDS Children's Center of Excellence on the campus of Mulago Hospital in Kampala, Uganda.

Bristol-Myers Squibb Appoints Christopher Perley as Devens General Manager

Thu, 2 Oct 2008 12:00:00 UT

DEVENS, Mass.--(BUSINESS WIRE)--

U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients

Wed, 1 Oct 2008 22:01:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food & Drug Administration (FDA) approved the use of REYATAZ

Thirteen Advocacy Groups Collaborate on New Online Resource Dedicated to Patients with Advanced Breast Cancer

Wed, 1 Oct 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Today, those living with advanced breast cancer now have an online resource available specifically for them. AdvancedBreastCancerCommunity.org is the first

Bristol-Myers Squibb to Commence Cash Tender Offer for ImClone Systems at $62.00 per share

Mon, 22 Sep 2008 23:01:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it is increasing its initial offer for ImClone Systems Incorporated (NASDAQ: IMCL) and intends to

ERBITUX(R) Five-Year Data Show Significant Improvement in Overall Survival for Patients with Locally or Regionally Advanced Head and Neck Cancer

Mon, 22 Sep 2008 19:00:00 UT

NEW YORK--(BUSINESS WIRE)--

Bristol-Myers Squibb Announces Filing of IPO Registration Statement for Mead Johnson Nutrition Company

Mon, 15 Sep 2008 21:16:00 UT

NEW YORK--(BUSINESS WIRE)--

Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year

Mon, 15 Sep 2008 14:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--

Bristol-Myers Squibb to Present at Healthcare Conference

Mon, 15 Sep 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--

Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year

Mon, 15 Sep 2008 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) today announced updated survival data from three Phase 2 studies of ipilimumab in patients with advanced

Bristol-Myers Squibb Submits Letter to ImClone Board of Directors

Thu, 11 Sep 2008 14:54:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) submitted the following letter to ImClone Systems Incorporated (NASDAQ: IMCL) Board of Directors today:

Study Published in New England Journal of Medicine Shows ERBITUX(R) Improved Survival in First-Line Recurrent And/Or Metastatic Head and Neck Cancer

Wed, 10 Sep 2008 21:02:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb

Bristol-Myers Squibb Announces Dividend

Tue, 9 Sep 2008 20:15:00 UT

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of

ONGLYZATM (saxagliptin) With Metformin as Initial Combination Therapy Significantly Lowered A1C and Demonstrated Significant Improvements Across Key Measures of Glucose Control in Treatment Naïve People With Type 2 Diabetes

Tue, 9 Sep 2008 12:00:00 UT

ROME--(BUSINESS WIRE)--Results from a 24-week Phase III study presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that ONGLYZA™ (saxagliptin), an investigational

Bristol-Myers Squibb Announces Dividend

Tue, 9 Sep 2008 12:00:00 UT

ONGLYZA(TM) (saxagliptin) With Metformin as Initial Combination Therapy Significantly Lowered A1C and Demonstrated Significant Improvements Across Key Measures of Glucose Control in Treatment Naive People With Type 2 Diabetes

Tue, 9 Sep 2008 10:01:00 UT

ROME--(BUSINESS WIRE)--Results from a 24-week Phase III study presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated

ONGLYZA(TM) (saxagliptin) Demonstrated Significant Improvements Across Key Measures of Glucose Control When Added to a Sulfonylurea or Thiazolidinedione in People With Inadequately Controlled Type 2 Diabetes

Mon, 8 Sep 2008 11:00:00 UT

ROME--(BUSINESS WIRE)--Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated

Bristol-Myers Squibb and AstraZeneca to Hold Investor Teleconference to Discuss EASD Highlights

Wed, 3 Sep 2008 13:15:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca

New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients

Tue, 2 Sep 2008 12:00:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) announced today the results of a Phase 2 dose-ranging study (APPRAISE-1) involving the investigational

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESC Highlights

Thu, 28 Aug 2008 16:30:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will host a conference call at 8:30 a.m. (ET) on Wednesday, September 3

Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program

Tue, 26 Aug 2008 12:00:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical development program today. The companies announced that new

Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma

Tue, 19 Aug 2008 20:00:00 UT

PRINCETON, N.J. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and

ADDING MULTIMEDIA NJ, CT, NY & MD School Districts Join Program That Teaches High School Students How Medicines Are Made

Wed, 13 Aug 2008 20:24:00 UT

SKILLMAN, N.J.--(BUSINESS WIRE)--A laboratory experiment that demonstrates how easily disease can spread, procedures to assure the safety of medicines, and learning how clinical trials are

CORRECTING and REPLACING CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender

Wed, 6 Aug 2008 01:23:00 UT

MEXICO CITY--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The corrected version reads:

BRISTOL-MYERS SQUIBB LAUNCHES SECURE THE FUTURE(R) TECHNICAL ASSISTANCE PROGRAM TO OPTIMIZE COMMUNITY SERVICES FOR COMPREHENSIVE HIV MANAGEMENT IN SUB-SAHARAN AFRICA

Tue, 5 Aug 2008 17:00:00 UT

MEXICO CITY--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and the

Bristol-Myers Squibb Announces Completion of ConvaTec Divestiture

Fri, 1 Aug 2008 17:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that Nordic Capital Fund VII and Avista Capital Partners

Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash

Thu, 31 Jul 2008 11:59:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has proposed to enter into an agreement to acquire ImClone Systems Incorporated (NASDAQ: IMCL), a

Bristol-Myers Squibb Continues Strong Financial Performance Led by Double-Digit Global Sales Growth

Thu, 24 Jul 2008 11:29:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reported very strong sales and earnings growth for the second

Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA(TM) (saxagliptin) for the Treatment of Type 2 Diabetes

Wed, 23 Jul 2008 12:00:00 UT

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and

Bristol-Myers Squibb Names Chief Procurement Officer

Mon, 21 Jul 2008 11:30:00 UT

NASSAU PARK, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that Quentin Roach has been named senior vice

Bristol-Myers Squibb to Announce Results for the Second Quarter of 2008 on July 24

Tue, 15 Jul 2008 17:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter of 2008 on

Bristol-Myers Squibb Endorses PhRMA's Code on Interactions with Health Care Professionals

Thu, 10 Jul 2008 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb is committed to following the highest ethical standards and all legal requirements in our promotion of drugs to health care professionals. Our drug promotion is guided by

Bristol-Myers Squibb Completes Acquisition of Kosan Biosciences Incorporated

Thu, 26 Jun 2008 21:39:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has completed its previously announced $190 million acquisition of Kosan Biosciences

Bristol-Myers Squibb Completes Tender Offer for Kosan Biosciences Incorporated

Thu, 26 Jun 2008 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that stockholders of Kosan Biosciences Incorporated (NASDAQ: KOSN) (

Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of Kosan Biosciences Incorporated

Wed, 18 Jun 2008 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino review period for its tender offer for Kosan Biosciences Incorporated

Data from Phase II Exploratory Study Suggest That ORENCIA(R) (abatacept) May Delay Development of Rheumatoid Arthritis in Adults with Undifferentiated Inflammatory Arthritis

Fri, 13 Jun 2008 16:37:00 UT

PARIS--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results from an exploratory Phase II study of 56

ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis

Thu, 12 Jun 2008 12:02:00 UT

PARIS--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results of radiographic analyses from the AIM (

Bristol-Myers Squibb Announces Dividend

Tue, 10 Jun 2008 20:30:00 UT

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of

ONGLYZA(TM) (saxagliptin) Demonstrated Significant Reductions in Key Measures of Glucose Control in Treatment Naive People with Type 2 Diabetes

Sat, 7 Jun 2008 17:03:00 UT

SAN FRANCISCO--(BUSINESS WIRE)--Results from a 24-week Phase III study presented at the 68th American Diabetes Association Annual Scientific Sessions demonstrated

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ADA Highlights

Thu, 5 Jun 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will host a conference call at 8:30 a.m. (ET) on Wednesday, June

ADDING MULTIMEDIA Newark High School Students and Research Scientists Discuss Challenges of Making Medicines

Mon, 2 Jun 2008 20:55:00 UT

NEWARK, N.J.--(BUSINESS WIRE)--More than 75 Newark high school students and teachers today probe the challenges and complexities of making medicines when they interact with research

New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of Clinical Oncology Annual Meeting

Sun, 1 Jun 2008 19:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and

ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Sat, 31 May 2008 17:37:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and

Bristol-Myers Squibb Reaffirms 2008 Earnings Guidance

Thu, 29 May 2008 20:30:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reaffirmed its 2008 earnings guidance for fully diluted

Bristol-Myers Squibb Begins Tender Offer to Acquire Kosan Biosciences Inc.

Thu, 29 May 2008 19:20:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) is commencing today, through its wholly owned subsidiary KB Acquisition Corp., a cash tender offer to purchase all

Bristol-Myers Squibb to Acquire Kosan Biosciences

Thu, 29 May 2008 13:22:00 UT

PRINCETON, N.J. and HAYWARD, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Kosan Biosciences Inc. (NASDAQ: KOSN) announced today that the companies have signed a

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

Wed, 28 May 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will host a conference call at 4:30 p.m. (ET) on Monday, June 2 to

Bristol-Myers Squibb to Present at Healthcare Conference

Tue, 27 May 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Sanford Bernstein Conference on Friday, May 30,

New Data on Bristol-Myers Squibb Oncology Compounds to Be Featured in More Than 100 Abstracts at ASCO 2008

Thu, 15 May 2008 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--More than 100 scientific abstracts on six Bristol-Myers Squibb Company (NYSE:BMY) oncology compounds

Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular Disease

Tue, 13 May 2008 13:00:00 UT

PRINCETON, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and KAI Pharmaceuticals, Inc., a privately held biotechnology company, today announced an

ABILIFY(R) (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric Patients (Aged 10-17) With Manic and Mixed Episodes of Bipolar I Disorder and Adolescents (Aged 13-17) With Schizophrenia

Thu, 8 May 2008 21:20:00 UT

TOKYO & PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. and

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Add-On Treatment to Lithium or Valproate in the Acute Treatment of Adults With Manic and Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features

Thu, 8 May 2008 21:13:00 UT

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and

Bristol-Myers Squibb to Present at Healthcare Conference

Wed, 7 May 2008 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present today at the 33rd Annual Deutsche Bank Healthcare Conference. Lamberto Andreotti,

Nordic Capital Fund VII and Avista Capital Partners Agree to Acquire ConvaTec Business for approximately $4.1 Billion

Fri, 2 May 2008 19:59:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today it has signed a definitive agreement to sell

ConvaTec Upgrades Flexi-Seal(R) Fecal Management System to Increase Ease of Use

Fri, 2 May 2008 15:56:00 UT

SKILLMAN, N.J.--(BUSINESS WIRE)--ConvaTec, a world-leading manufacturer of ostomy and wound care products, today announced that

Bristol-Myers Squibb Invites Public to Listen to Webcast of 2008 Annual Meeting

Wed, 30 Apr 2008 12:00:00 UT

Bristol-Myers Squibb Issues $1.6 Billion of Senior Notes

Tue, 29 Apr 2008 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has agreed to sell $1.6 billion of senior unsecured notes: $600 million in aggregate principal amount of 5.450% notes due May

BARACLUDE® (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients

Sat, 26 Apr 2008 12:00:00 UT

MILAN, Italy--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced new data from the E.A.R.L.Y. study (ETV-079), in which treatment of antiviral-naive adult chronic hepatitis B patients with

Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab

Fri, 25 Apr 2008 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Medarex, Inc. (NASDAQ: MEDX) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that, after meeting with the U.S. Food and Drug Administration (FDA), the companies will delay

Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company

Thu, 24 Apr 2008 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported strong double-digit net sales growth and solid earnings growth for the first quarter 2008 and reaffirmed 2008 earnings guidance.

Bristol-Myers Squibb Appoints Treasurer

Wed, 23 Apr 2008 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the appointment of Jeffrey Galik to the position of vice president and treasurer. In this role, Galik will be responsible for the

Mead Johnson Announces Renewable-Energy Project

Tue, 22 Apr 2008 12:00:00 UT

EVANSVILLE, Ind.--(BUSINESS WIRE)--Mead Johnson Nutritionals today announced plans for an innovative project that will use landfill gas for energy at the company’s manufacturing facility in Evansville. The gas

Bristol-Myers Squibb to Announce Results for the First Quarter of 2008 on April 24

Thu, 17 Apr 2008 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the first quarter of 2008 on Thursday, April 24. During a 10:30 a.m. (ET) conference call on April 24, company executives

U.S. Food and Drug Administration Approves ORENCIA® (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older

Tue, 8 Apr 2008 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ORENCIA® (abatacept) for reducing signs and symptoms in

BARACLUDE® (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients

Mon, 24 Mar 2008 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--New BARACLUDE® (entecavir) data presented today demonstrated a continued low incidence of resistance in nucleoside-naive patients through five years of treatment. In the

Bristol-Myers Squibb to Present at Healthcare Conferences

Mon, 17 Mar 2008 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will present at the Cowen and Company 28th Annual Health Care Conference today. Brian Daniels, M.D., senior vice president, Global Development, will

New 300mg Loading Dose Tablet For Plavix® Receives Positive Opinion From The European Committee For Medicinal Products (CHMP)

Wed, 5 Mar 2008 13:00:00 UT

PARIS & PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the

Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer

Wed, 5 Mar 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the company's Board of Directors has elected Jean-Marc Huet senior vice president and chief financial officer, effective March

Bristol-Myers Squibb Announces Dividend

Tue, 4 Mar 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE: BMY) today declared a quarterly dividend of thirty-one cents ($0.31) per share on the $.10 par value Common Stock of the

U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated with Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)

Fri, 29 Feb 2008 13:00:00 UT

TOKYO & PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug

Great Comebacks® Program Announces 2007 National Award Winner

Wed, 27 Feb 2008 13:00:00 UT

WASHINGTON--(BUSINESS WIRE)--Scott Ellis, a firefighter from Enfield, Connecticut was named this year’s Great Comebacks® National Award recipient this evening at a ceremony in Washington, D.C. Founded in

Celebrity Chef Sandra Lee Offers Recipes and Shortcuts in the Kitchen to People with Rheumatoid Arthritis

Wed, 27 Feb 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Life and Style Expert Sandra Lee's Semi-Homemade approach to cooking, which involves using 70 percent store-bought items and 30 percent homemade items in every meal, makes life easier for

Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board

Tue, 12 Feb 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the company's Board of Directors has elected James M. Cornelius chairman of the Board. Mr. Cornelius, who was named chief

CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ® (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients

Wed, 6 Feb 2008 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results from the CASTLE study, in which 300 mg of once-daily REYATAZ® (atazanavir sulfate) taken with 100 mg of ritonavir

Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007

Thu, 31 Jan 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the fourth quarter and twelve months ended December 31, 2007 and revised 2008 earnings guidance primarily to

Bristol-Myers Squibb Names Togo D. West, Jr. to Board of Directors

Tue, 22 Jan 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that Togo D. West, Jr. has been elected to its Board of Directors, effective today. West will serve as a member of the Compensation

Bristol-Myers Squibb Announces Closing of Its Barceloneta, Puerto Rico Plant

Fri, 18 Jan 2008 13:00:00 UT

BARCELONETA, Puerto Rico--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today it will cease operations at its Barceloneta manufacturing plant by the end of 2008.

Bristol-Myers Squibb to Announce Results for the Fourth Quarter and Full Year of 2007 on January 31

Wed, 16 Jan 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the fourth quarter and full year of 2007 on Thursday, January 31. During a 10 a.m. (ET) conference call on Jan. 31, company

Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging

Tue, 8 Jan 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Avista Capital Partners, a leading private equity firm, announced today that Avista has completed its acquisition of Bristol-Myers Squibb Medical

European Commission Approves ATRIPLA® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection

Mon, 17 Dec 2007 13:00:00 UT

PRINCETON, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)--The European Commission has granted marketing authorization for ATRIPLA® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg),

Avista Capital Partners Agrees to Acquire Bristol-Myers Squibb Medical Imaging for Approximately $525 Million

Mon, 17 Dec 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Avista Capital Partners, a leading private equity firm, announced today the parties have signed a definitive agreement for Avista to acquire

Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe

Tue, 11 Dec 2007 13:00:00 UT

PRINCETON, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (NASDAQ: GILD) today announced an agreement to commercialize ATRIPLA® (efavirenz 600

Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma

Mon, 10 Dec 2007 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Medarex, Inc. (NASDAQ: MEDX) and Bristol-Myers Squibb Company (NYSE: BMY) today announced top-line data from the three registrational trials (008, 022, 007) that constitute the

Governor Riley Announces Grant to Improve Mental Health Services in the Black Belt

Wed, 5 Dec 2007 14:00:00 UT

MONTGOMERY, Ala.--(BUSINESS WIRE)--Governor Bob Riley announced Wednesday that the Bristol-Myers Squibb Foundation has awarded Alabama a $1.2 million grant to improve mental health services in the Black Belt.

Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community

Wed, 5 Dec 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--During a meeting with investors today, Bristol-Myers Squibb Company (NYSE: BMY) will conduct a comprehensive review of its business and research and development operations, and outline its

Bristol-Myers Squibb Announces Closing Of Its Colón, Panama Manufacturing Facility

Tue, 4 Dec 2007 13:00:00 UT

COLÓN, Panama--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today it will cease operations at Bristol Laboratories International Sociedad Anónima, a secondary packaging facility in

Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors

Tue, 4 Dec 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that Alan J. Lacy has been elected to its Board of Directors, effective January 2, 2008. Lacy will serve as a member of the Audit

Bristol-Myers Squibb Joins with NJ Children's Hospital in Launching New Center for Immune System Disorders and Infectious Diseases Including HIV/AIDS

Thu, 29 Nov 2007 13:00:00 UT

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Underscoring its worldwide commitment to children with HIV/AIDS, Bristol-Myers Squibb today joined Robert Wood Johnson University Hospital in commemorating the opening of a new

Bristol-Myers Squibb to Webcast December 5 Business Update

Wed, 28 Nov 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will provide a business update to the investment community on Wednesday, December 5 from 1 p.m. to 5 p.m. (EST).

World AIDS Day Campaign to Shine a Light of Hope on the HIV/AIDS Epidemic in the United States

Tue, 27 Nov 2007 13:00:00 UT

PRINCETON, N.J. & WASHINGTON--(BUSINESS WIRE)--Bristol- Myers Squibb Company (NYSE: BMY) in collaboration with the National AIDS Fund (NAF) today launched the fourth annual "Light to Unite" campaign in support of World

Lucia Nthunya is a Volunteer Mom

Mon, 26 Nov 2007 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Lucia Nthunya has 50 children in a region where some 40 percent of the people are infected with HIV/AIDS.

Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status

Fri, 23 Nov 2007 13:00:00 UT

PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--Bristol- Myers Squibb Company (NYSE: BMY) and Pierre Fabre Medicament reported today that they are terminating their license agreement for the development of vinflunine, a

Bristol-Myers Squibb Foundation Donates $6 Million to University Medical Center at Princeton Foundation

Wed, 21 Nov 2007 14:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--A $6 million grant from the Bristol-Myers Squibb Foundation will help create a new community health care center at the University Medical Center at Princeton (UMCP) to provide

U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)

Tue, 20 Nov 2007 13:00:00 UT

Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE® as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood Pressure Goals

Mon, 19 Nov 2007 13:00:00 UT

PARIS & PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved the

Thandeka Hlomuka Needs to be Strong for Her Sisters

Thu, 15 Nov 2007 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--In a remote, rural village in South Africa, a young woman named Thandeka Hlomuka lives with her two younger sisters in the house where their mother died last year of AIDS.

Mead Johnson Nutritionals And Indiana University School Of Medicine Develop Center For Nutrition And Immunity

Thu, 15 Nov 2007 13:00:00 UT

EVANSVILLE, Ind.--(BUSINESS WIRE)--Mead Johnson Nutritionals and Indiana University School of Medicine (IUSM) announced the development of a Center for Nutrition and Immunity that will focus on research related to

ABILIFY® (aripiprazole) Supplemental New Drug Application For The Treatment Of Pediatric Patients With Bipolar I Disorder Accepted For Priority Review By The U.S. Food And Drug Administration

Thu, 15 Nov 2007 13:00:00 UT

New England Journal of Medicine Study Shows ERBITUX® Improves Survival in Advanced Colorectal Cancer

Wed, 14 Nov 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today results from a multicenter, open-label, randomized Phase III trial, published in the

The Bristol-Myers Squibb Foundation Combats Chronic Hepatitis B in Asia

Tue, 13 Nov 2007 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Yet, for the millions infected, significant disparities in care and treatment remain and a wide range of barriers exist that must be overcome in order to help them. Addressing health

Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA® (Abatacept)

Mon, 12 Nov 2007 13:00:00 UT

BOSTON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of three post-hoc analyses from two Phase III pivotal trials that showed ORENCIA® (abatacept) improved daily activity

Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA® (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate

Fri, 9 Nov 2007 13:00:00 UT

BOSTON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that cumulative five-year data from an open-label long-term extension of a Phase IIb trial demonstrate the long-term efficacy and safety

FDA Approves New SPRYCEL® (Dasatinib) Product Labeling for Patients with Chronic-Phase CML

Thu, 8 Nov 2007 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved new labeling for SPRYCEL to include a lower recommended starting

U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for Adolescent Patients with Schizophrenia

Tue, 6 Nov 2007 13:00:00 UT

Ninety-one Percent of BARACLUDE® (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels

Fri, 2 Nov 2007 12:00:00 UT

BOSTON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced data from a four-year cohort (ETV-022/901, n=146), which showed that 91 percent (98/108) of patients treated with BARACLUDE®

Our Employees Reach Out to Help Africa's Children Read

Thu, 1 Nov 2007 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Matsepo Ramabele and her grandchildren treasure their reading time every day and the three books they now own from the Bristol-Myers Squibb children's clinic. Eleven-year-old Bohlokoa says

Crohn’s & Colitis Foundation And Convatec Announce 2007 Great Comebacks® Program Regional Awards Recipients

Tue, 30 Oct 2007 12:00:00 UT

SKILLMAN, N.J.--(BUSINESS WIRE)--The Crohn’s & Colitis Foundation and ConvaTec, a world-leading manufacturer of ostomy and wound care products, announced today the regional recipients for the 2007 Great

Construction Starts on Children’s AIDS Center In Kenya

Mon, 29 Oct 2007 12:00:00 UT

HOUSTON--(BUSINESS WIRE)--Ground breaking ceremonies were held today in Kisumu, Kenya, for a comprehensive center to provide pediatric HIV/AIDS care -- the latest effort by the Baylor International Pediatric AIDS

Bristol-Myers Squibb Company Reports Financial Results for the Third Quarter and First Nine Months of 2007

Thu, 25 Oct 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the third quarter and nine months ended September 30, 2007 and updated earnings guidance for the full year.

European CHMP Issues Positive Opinion for ATRIPLA® (Efavirenz 600 Mg/ Emtricitabine 200 Mg/Tenofovir Disoproxil Fumarate 300 Mg)

Thu, 18 Oct 2007 12:00:00 UT

PRINCETON, N.J. & FOSTER CITY, Calif. & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY), Gilead Sciences, Inc. (NASDAQ: GILD) and Merck & Co., Inc. (NYSE: MRK) announced today

Health Canada Approves ATRIPLA® (Efavirenz 600 Mg/Emtricitabine 200 Mg/ Tenofovir Disoproxil Fumarate 300 Mg), the First Once-Daily Single Tablet Regimen for HIV

Wed, 17 Oct 2007 12:00:00 UT

PRINCETON, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (NASDAQ: GILD) announced today that Health Canada has approved ATRIPLA® (efavirenz 600

ImClone and Bristol-Myers Squibb Announce Joint Agreement with Merck KgaA to Co-Develop and Co-Commercialize ERBITUX® in Japan

Wed, 17 Oct 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have established an agreement with Merck KGaA for the co-development and

ImClone and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan

Wed, 17 Oct 2007 09:00:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have established an agreement with Merck KGaA

FDA Approves IXEMPRA™ (Ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer

Tue, 16 Oct 2007 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of IXEMPRA™ (ixabepilone) as monotherapy for the

Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25

Mon, 8 Oct 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the third quarter of 2007 on Thursday, October 25. During a conference call on October 25 at 10:30 a.m. (ET), financial

Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports Use as a Single Agent in Patients with Advanced Colorectal Cancer

Wed, 3 Oct 2007 00:18:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has

High School Students In Five States Learn How Medicines Are Made

Fri, 28 Sep 2007 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Eric Maiorino, a biology teacher at Malcolm X Shabazz High School in Newark, New Jersey, is prepared for the new school year, enthusiastically looking forward to teaching “real

Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices

Fri, 28 Sep 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has finalized a civil settlement agreement with the United States Department of Justice ("DOJ") and the Office of the United

Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing

Thu, 27 Sep 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) announced today that Dr. Jeremy Levin has joined the company's Research and Development organization as senior vice president, External Science, Technology

FDA Approves New 300mg Loading Dose Tablet for PLAVIX® (clopidogrel bisulfate)

Thu, 27 Sep 2007 12:00:00 UT

BRIDGEWATER & PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved a

Bristol-Myers Squibb to Acquire Adnexus Therapeutics

Mon, 24 Sep 2007 12:00:00 UT

PRINCETON, N.J. & WALTHAM, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Adnexus™ Therapeutics announced today the companies have signed a definitive agreement under which Bristol-Myers

Construction Begins for First Pediatric HIV/AIDS Medical Center in West Africa

Mon, 24 Sep 2007 12:00:00 UT

BOBO DIOULASSO, Burkina Faso--(BUSINESS WIRE)--Construction begins today on the first pediatric HIV/AIDS medical center in West Africa. Located in Burkina Faso, one of the world’s most resource constrained

New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL® as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies

Tue, 18 Sep 2007 12:00:00 UT

EVANSVILLE, Ind.--(BUSINESS WIRE)--A recently published study of 4 year olds who had been fed Enfamil LIPIL® infant formula exclusively for their first 17 weeks of life has become the longest-term analysis of its

Screen and Stage Legend Phylicia Rashad Launches a Campaign Close to Her Heart

Thu, 13 Sep 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--One of America's best-loved TV moms, The Cosby Show's Phylicia Rashad is taking on a new leading role in raising awareness of Peripheral Artery Disease (P.A.D.), a condition that affects

Bristol-Myers Squibb Announces Dividend

Tue, 11 Sep 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE: BMY) today declared a quarterly dividend of twenty-eight cents ($0.28) per share on the $.10 par value Common Stock of the

ERBITUX® Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

Tue, 11 Sep 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that a Phase III study of ERBITUX® (Cetuximab) in combination with platinum-based

Bristol-Myers Squibb to Present at Bear Stearns Healthcare Conference, Reaffirms Financial Guidance

Mon, 10 Sep 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) Chief Executive Officer James M. Cornelius will present this afternoon at 2:30 EDT at the Bear Stearns 20th Annual Healthcare Conference in New York

Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program

Mon, 27 Aug 2007 12:00:00 UT

NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Bristol-Myers Squibb Company (NYSE: BMY) ("companies") today announced that they have finalized a definitive agreement for the worldwide

ConvaTec Launches Moldable Technology™, Custom-Fitting Skin Barriers

Wed, 15 Aug 2007 12:00:00 UT

SKILLMAN, N.J.--(BUSINESS WIRE)--ConvaTec, a world-leading manufacturer of ostomy and wound care products, announced today the U.S. availability of the ConvaTec Moldable Technology™ line of ostomy skin barriers,

Educators, Pharmaceutical Industry Team Up to Teach Students How Medicines Are Made

Tue, 14 Aug 2007 12:00:00 UT

SKILLMAN, N.J.--(BUSINESS WIRE)--Fifty-nine high school teachers from 19 New Jersey, New York, Massachusetts, Pennsylvania and Iowa high schools this week are preparing to teach their students how medicines are made in

ORENCIA® (Abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review

Tue, 7 Aug 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the supplemental biologics license application

Bristol-Myers Squibb and Imclone Systems Significantly Expand Erbitux Clinical Development Program

Fri, 27 Jul 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the companies have amended the terms of their agreement for the co- development

Expansion of Pediatric AIDS Programs Set for Lesotho

Thu, 26 Jul 2007 14:00:00 UT

HOUSTON--(BUSINESS WIRE)--The Baylor International Pediatric AIDS Initiative (BIPAI) will increase the number of physicians it has assigned to Lesotho and build satellite clinics in scaling up its commitment to assist

Bristol-Myers Squibb Company Reports Financial Results for the Second Quarter and First Half of 2007

Thu, 26 Jul 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the second quarter and six months ended June 30, 2007 and raised earnings guidance for the full year.

Bicycling Magazine’s Second Annual Biketown Africa Aims to Improve Health Care in Africa One Bike at a Time

Tue, 24 Jul 2007 14:00:00 UT

EMMAUS, Pa.--(BUSINESS WIRE)--Bicycling magazine, published by Rodale Inc., and Kona Bicycling Company have teamed up for the second annual BikeTown Africa. This year, BikeTown Africa selected two destinations: Katima,

Bristol-Myers Squibb's SECURE THE FUTURE® Program Offers New Approach to Replicate Successful HIV Treatment Support Model

Mon, 23 Jul 2007 12:00:00 UT

SYDNEY, Australia--(BUSINESS WIRE)--Today Bristol-Myers Squibb announced a new approach to expand its SECURE THE FUTURE® program in the developing world through replicating its most successful HIV treatment

ABILIFY® (Aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food and Drug Administration for Adjunctive Treatment in Adults with Major Depressive Disorder

Tue, 17 Jul 2007 12:00:00 UT

Data Available from ERBITUX® Phase III Study in First-Line Treatment of Advanced Lung Cancer

Thu, 12 Jul 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced results from an open-label Phase III study of ERBITUX® (Cetuximab) plus a taxane

Bristol-Myers Squibb to Announce Results for the Second Quarter of 2007 on July 26

Mon, 9 Jul 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the second quarter of 2007 on Thursday, July 26. During a conference call on July 26 at 10:30 a.m. (ET), financial

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

Fri, 6 Jul 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Results from a Phase II study - which will be published in the August 10, 2007 issue of the Journal of Clinical Oncology (JCO) and are now available as an Early Release Article at

Bristol-Myers Squibb Signs Agreement for Sale of Bufferin® and Excedrin® to Lion Corporation in Japan, Asia and Oceania

Fri, 29 Jun 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) has signed an agreement for the sale of the Bufferin® and Excedrin® brands in Japan, Asia (excluding China and Taiwan) and certain Oceaniac

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

Mon, 25 Jun 2007 12:00:00 UT

CHICAGO--(BUSINESS WIRE)--Phase III data presented this week at the annual meeting of the American Diabetes Association demonstrated that saxagliptin, an inhibitor of dipeptidyl-peptidase-4 (DPP-4) in development by

First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes

Mon, 25 Jun 2007 12:00:00 UT

CHICAGO--(BUSINESS WIRE)--In a 14-day, Phase IIa study of the safety profile of multiple doses of the investigational compound dapagliflozin, a selective inhibitor of the Sodium-Glucose Transporter 2 (SGLT2)

Sanofi-Aventis and Bristol-Myers Squibb Prevail in U.S. Plavix Patent Litigation

Tue, 19 Jun 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb Company (New York: NYSE: BMY) announced today that the U.S. District Court for the Southern

FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Ixabepilone

Tue, 19 Jun 2007 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the New Drug Application (NDA) for the

Bristol-Myers Squibb to Announce Results for the Fourth Quarter and Full Year of 2006 on January 25

Sun, 17 Jun 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the fourth quarter and full year of 2006 on Thursday, January 25. During a conference call on January 25 at 10:30 a.m. (ET),

Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia® (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy

Fri, 15 Jun 2007 12:00:00 UT

BARCELONA, Spain--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results regarding the efficacy and safety of ORENCIA® (abatacept) from the open-label phase of an ongoing investigational

Statement on the Deferred Prosecution Agreement Following Press Release From U.S. Attorney

Thu, 14 Jun 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) today acknowledged the statement by the Hon. Christopher J. Christie, the U.S. Attorney for the District of New Jersey, regarding tomorrow's expiration of the

Ascent With A Handicap: Rob Hill Climbs Germany's Zugspitze

Thu, 14 Jun 2007 12:00:00 UT

GARMISCH-PARTENKIRCHEN/ZUGSPITZE, BAVARIA, GERMANY--(BUSINESS WIRE)--Despite his ostomy (stoma), Canadian Rob Hill today climbed from Garmisch-Partenkirchen up the Zugspitze -- the highest mountain in Germany. Doing

Bristol-Myers Squibb Announces Dividend

Tue, 12 Jun 2007 12:00:00 UT

U.S. Department of Justice Investigation of Bristol-Myers Squibb in Proposed Plavix Patent Settlement Is Resolved

Mon, 11 Jun 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today pleaded guilty to two counts of violating 18 U.S.C. Sec. 1001 in U.S. District Court for the District of Columbia. This guilty plea resolved as

FDA Accepts and Grants Priority Review of Erbitux® (Cetuximab) sBLA for Overall Survival in Patients With Advanced Colorectal Cancer

Mon, 11 Jun 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review,

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab

Tue, 5 Jun 2007 12:00:00 UT

CHICAGO--(BUSINESS WIRE)--Medarex, Inc. (NASDAQ: MEDX) and Bristol-Myers Squibb Company (NYSE: BMY) today presented results from multiple clinical studies of ipilimumab (MDX-010), an investigational immunotherapy, for

ABILIFY® (aripiprazole) Supplemental New Drug Application For Pediatric Patients With Schizophrenia Accepted For Priority Review By The U.S. Food And Drug Administration

Tue, 5 Jun 2007 12:00:00 UT

TOKYO & PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co, Ltd., and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority (six

Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer

Sun, 3 Jun 2007 12:00:00 UT

CHICAGO--(BUSINESS WIRE)--Today, Bristol-Myers Squibb (NYSE: BMY) reported results from a large randomized Phase III study of the investigational compound ixabepilone in patients with breast cancer whose disease had

BIPAI Center Of Excellence To Be Established In Kenya

Fri, 1 Jun 2007 12:00:00 UT

HOUSTON--(BUSINESS WIRE)--The Baylor College of Medicine International Pediatric AIDS Initiative (BIPAI), Texas Children’s Hospital in Houston and the Kenya Ministry of Health have announced today an agreement to

Bristol-Myers Squibb Indiana Manufacturing Facilities Achieve Department Of Labor’s OSHA “Star” Status

Wed, 30 May 2007 12:00:00 UT

EVANSVILLE, Ind.--(BUSINESS WIRE)--Bristol-Myers Squibb Company’s (NYSE: BMY) pharmaceutical manufacturing facilities in Evansville and Mount Vernon, Indiana have earned the Indiana Department of Labor’s

Investigational Study Evaluates The Effectiveness Of Aripiprazole In Adolescents With Schizophrenia

Wed, 23 May 2007 12:00:00 UT

SAN DIEGO--(BUSINESS WIRE)--In a six-week study in adolescents (13-17 years old) with schizophrenia, the Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) atypical antipsychotic aripiprazole

Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants

Mon, 21 May 2007 12:00:00 UT

SAN DIEGO--(BUSINESS WIRE)--In adults with major depressive disorder, adding aripiprazole to antidepressant therapy (ADT) resulted in significant improvement in the primary endpoint, the Montgomery- Asberg Depression

BARACLUDE® (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients

Mon, 21 May 2007 12:00:00 UT

WASHINGTON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced new data from study ETV-079, which showed that treatment with BARACLUDE® (entecavir) demonstrated greater viral load reduction

Bristol-Myers Squibb Announces Agreement in Principle to Resolve Federal Antitrust Investigation

Thu, 10 May 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and the Antitrust Division of the U.S. Department of Justice (DOJ) have reached an agreement in principle to resolve the previously disclosed DOJ

Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration With Isis Pharmaceuticals

Wed, 9 May 2007 12:00:00 UT

PRINCETON, N.J. & CARLSBAD, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced a collaboration to discover, develop and commercialize novel

'AIM for the B' Public Education Program To Raise Awareness of Chronic Hepatitis B Among Communities Most Affected by the Disease

Mon, 7 May 2007 12:00:00 UT

PRINCETON, N.J. & DOYLESTOWN, Pa.--(BUSINESS WIRE)--Today, Bristol-Myers Squibb and the Hepatitis B Foundation announced the launch of the fourth annual "AIM for the B: Awareness, Involvement and Mobilization for

Bristol-Myers Squibb Breaks Ground on new Biologics Manufacturing Facility in Massachusetts

Wed, 2 May 2007 12:00:00 UT

DEVENS, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) executives were joined by Governor Deval Patrick, state and local officials, community leaders and MassDevelopment today for a groundbreaking

Bristol-Myers Squibb Company Reports First Quarter 2007 Financial Results

Thu, 26 Apr 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the first quarter of 2007 and raised earnings guidance for the full year.

James M. Cornelius Elected Bristol-Myers Squibb CEO

Thu, 26 Apr 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that James M. Cornelius, who has served as interim chief executive for the past eight months, has been elected chief executive officer

Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds

Thu, 26 Apr 2007 12:00:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol- Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) ("companies") today announced a worldwide collaboration to develop and commercialize apixaban, an

FDA Approves Labeling Update For ORENCIA® (abatacept) To Inhibit Structural Joint Damage In Adults With Moderate To Severe Rheumatoid Arthritis

Wed, 25 Apr 2007 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approved an update to the ORENCIA® (abatacept) product labeling regarding

Bristol-Myers Squibb Invites Public to Listen to Webcast of its 2007 Annual Meeting

Tue, 24 Apr 2007 12:00:00 UT

Crohn’s Patient Robert Hill Summits Carstensz Pyramid, Sixth In Seven Summits Campaign

Mon, 23 Apr 2007 12:00:00 UT

SKILLMAN, N.J.--(BUSINESS WIRE)--Crohn’s disease patient Robert (Rob) Hill has summited Carstensz Pyramid (16,023 feet, 4,884 meters), the highest peak on the Oceanic continent. Hill’s team began the climb

Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

Mon, 16 Apr 2007 17:45:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced detailed results from the EPIC study

Randomized Phase III Trial Showed ERBITUX® (Cetuximab) Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

Mon, 16 Apr 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced detailed results from the EPIC study – a randomized, open-label, multi-center

Broadway Actress/HIV Advocate, Sheryl Lee Ralph, Unveils Winning Photographs in Contest Communicating Personal Experiences with HIV/AIDS Through Photography

Mon, 16 Apr 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Broadway actress and HIV advocate Sheryl Lee Ralph today unveiled the winning photographs of Bristol-Myers Squibb Company's (NYSE: BMY) REYATAZ® (atazanavir sulfate) "Fight HIV Your Way"

Bristol-Myers Squibb to Announce Results for the First Quarter of 2007 on April 26

Mon, 16 Apr 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the first quarter of 2007 on Thursday, April 26. During a conference call on April 26 at 10:30 a.m. (ET), financial

Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE® (entecavir) Resistance in Nucleoside-naive Chronic Hepatitis B Patients

Sat, 14 Apr 2007 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced new results of the BARACLUDE® (entecavir) resistance monitoring program, which found a continued low incidence of

BARACLUDE® (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

Fri, 13 Apr 2007 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced data from a cohort of nucleoside-naive HBeAg-negative chronic hepatitis B patients (ETV-027/901, n=99). These data showed that

Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

Tue, 10 Apr 2007 16:00:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that a Phase III study of ERBITUX

Rob Hill To Scale The Highest Mountain In Oceania For Intestinal Disease Awareness In Asia Pacific

Tue, 10 Apr 2007 12:00:00 UT

HONG KONG--(BUSINESS WIRE)--Intestinal disease sufferer Robert (Rob) Hill today launches his bid to be the first ostomate to climb the Seven Summits. This week, Hill will scale 16,023 feet (4,884 meters) to the summit

Data Available From Erbitux® Phase III Study In First-Line Treatment Of Advanced Pancreatic Cancer

Tue, 10 Apr 2007 12:00:00 UT

Survival Data Available From ERBITUX® Study in First-Line Treatment of Advanced Head and Neck Cancer

Wed, 4 Apr 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that a first line Phase III study of ERBITUX® (Cetuximab) combined with

Bristol-Myers Squibb Significantly Expands Research And Development Presence In India Through Collaborations With Biocon And Accenture

Wed, 14 Mar 2007 12:00:00 UT

BANGALORE, India--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced the company is expanding its research and development (R&D) capabilities in India. The increase is an integral part of the

Bristol-Myers Squibb Announces Dividend

Tue, 6 Mar 2007 13:00:00 UT

Bristol-Myers Squibb Names Michael Grobstein to Board of Directors

Tue, 6 Mar 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that its Board of Directors has elected Michael Grobstein, retired Vice Chairman, Ernst & Young, to the Board. His appointment is

Bristol-Myers Squibb Supports Area Robotics Teams

Thu, 1 Mar 2007 13:00:00 UT

LAWRENCEVILLE--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) today announced grants totaling $82,900 to support robotics teams at six central New Jersey school districts that will compete in the FIRST (For

Great Comebacks® Program Announces 2006 National Award Winners

Wed, 28 Feb 2007 13:00:00 UT

WASHINGTON--(BUSINESS WIRE)--Sandra Benitez, mother, teacher and author from Edina, MN, was named this year’s Great Comebacks® National Award recipient, and White House advisor Tony Snow was named Honorary

Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds

Mon, 26 Feb 2007 13:00:00 UT

PRINCETON, N.J. & WALTHAM, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Adnexus(TM) Therapeutics today announced a worldwide strategic alliance to discover, develop and commercialize

Bristol-Myers Squibb Completes Land Acquisition for New Biologics Facility

Fri, 16 Feb 2007 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) has completed the land purchase of an approximately 89-acre site from MassDevelopment for its new large-scale multi-product bulk biologics

Bristol-Myers Squibb Names Sandra Leung Senior Vice President and General Counsel

Thu, 15 Feb 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has appointed Sandra Leung as Senior Vice President and General Counsel. Leung will manage the Bristol-Myers Squibb legal

ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of ERBITUX in Metastatic Colorectal Cancer

Mon, 5 Feb 2007 13:00:00 UT

NEW YORK & TOKYO--(BUSINESS WIRE)--ImClone Systems (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that an application has been submitted with the Japanese Pharmaceuticals and Medical

Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2006 and Announces EPS Guidance for 2007

Thu, 25 Jan 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the fourth quarter and twelve months ended December 31, 2006 and announced 2007 earnings guidance.

Bristol-Myers Squibb Supports Local Emergency Services

Wed, 17 Jan 2007 13:00:00 UT

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) today announced more than $82,000 in grants for emergency services organizations in several central New Jersey communities. The contributions will

Bristol-Myers Squibb to Announce Results for the Fourth Quarter and Full Year of 2006 on January 25

Wed, 17 Jan 2007 13:00:00 UT

Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds

Thu, 11 Jan 2007 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca ("companies") today announced a collaboration to develop and commercialize two investigational compounds being studied for the

ERBITUX® Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer

Wed, 10 Jan 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that a Phase III study of ERBITUX® (cetuximab) plus FOLFIRI (an irinotecan- based

ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of ERBITUX in Metastatic Colorectal Cancer

Fri, 5 Jan 2007 13:00:00 UT

Canadian Federal Court of Appeals Rules in sanofi-aventis' Favor in the Canadian Plavix Notice of Compliance Proceedings

Thu, 28 Dec 2006 13:00:00 UT

Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan

Wed, 27 Dec 2006 13:00:00 UT

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced Otsuka has been granted exclusive rights in Japan to develop and commercialize the

Bristol-Myers Squibb Announces Agreement In Principle to Settle Federal Investigation Into Pricing, Sales And Marketing Practices

Thu, 21 Dec 2006 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) ("the Company"), the United States Department of Justice, and the Office of the United States Attorney for the District of Massachusetts have reached

Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Discover and Develop Novel Oncology Compounds

Mon, 18 Dec 2006 13:00:00 UT

SOUTH SAN FRANCISCO, Calif. & NEW YORK--(BUSINESS WIRE)--Exelixis, Inc. and Bristol-Myers Squibb Company today announced a worldwide collaboration to discover, develop and commercialize novel targeted therapies for the

North Carolina Department Of Labor Awards The Carolina Star To ConvaTec Manufacturing Site

Fri, 15 Dec 2006 13:00:00 UT

SKILLMAN, N.J.--(BUSINESS WIRE)--The North Carolina Department of Labor recertified ConvaTec’s Greensboro manufacturing site awarding the facility its second Carolina Star, which recognizes worksites that are

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss Data Presented at ASH Meeting

Wed, 13 Dec 2006 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will host a conference call on December 18 at 8:00 am (ET) to review data presented at the American Society of Hematology (ASH) 48th Annual Meeting

ABILIFY® (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available

Tue, 12 Dec 2006 13:00:00 UT

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY® (aripiprazole) Injection, an injectable form of

Study Of SPRYCEL® (dasatinib) Or 800 MG OF GLEEVEC®* (imatinib mesylate) Shows Patients Treated With SPRYCEL Achieved High Cytogenetic Responses And Prolonged Progression-free Survival

Mon, 11 Dec 2006 13:00:00 UT

ORLANDO, Fla.--(BUSINESS WIRE)--Today, Bristol-Myers Squibb Company (NYSE: BMY) announced results of a randomized Phase II study showing that a substantial number of patients with chronic-phase chronic myelogenous

Study Shows SPRYCEL® (dasatinib) 100 MG Once A Day Provides Responses Similar To Those In Patients Taking Approved 70 MG Twice A Day Dose, With Reduced Incidence Of Side Effects

Mon, 11 Dec 2006 13:00:00 UT

ORLANDO, Fla.--(BUSINESS WIRE)--Today, Bristol-Myers Squibb Company (NYSE: BMY) announced results from a randomized Phase III study showing that patients receiving SPRYCEL 100 mg once a day achieved similar cytogenetic

Preliminary Injunction Against Apotex Upheld on Appeal

Fri, 8 Dec 2006 13:00:00 UT

PARIS & NEW YORK--(BUSINESS WIRE)--Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb Company (New York: NYSE: BMY) (the "companies") announced today that the United States

ABILIFY® (aripiprazole) Demonstrated Efficacy as Long-Term Maintenance Therapy in Adults With Bipolar I Disorder Following Treatment for a Recent Manic Or Mixed Episode

Thu, 7 Dec 2006 13:00:00 UT

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Maintenance therapy with the Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. atypical antipsychotic ABILIFY® (aripiprazole) for nearly two

Bristol-Myers Squibb Announces Dividend

Tue, 5 Dec 2006 13:00:00 UT

Bristol-Myers Squibb Company Announces Voluntary Delisting From NYSE Arca

Fri, 1 Dec 2006 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it will voluntarily withdraw its securities from listing on NYSE Arca, Inc., formerly the Pacific Exchange. Bristol-Myers Squibb

Bristol-Myers Squibb and The National AIDS Fund Announce World AIDS Day Campaign to Shine a Light on the HIV/AIDS Epidemic in the United States

Mon, 27 Nov 2006 13:00:00 UT

WASHINGTON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) in cooperation with the National AIDS Fund today launched the third annual "Light to Unite" campaign in support of World AIDS Day. This year's

Crohn's and Colitis Foundation of America and ConvaTec Recognize Young Patients With Inflammatory Bowel Disease

Mon, 20 Nov 2006 13:00:00 UT

SKILLMAN, N.J.--(BUSINESS WIRE)--The Crohn's & Colitis Foundation of America (CCFA) and ConvaTec, a world-leading manufacturer of ostomy and wound care products, announced today the recipients of the Great

Bristol-Myers Squibb Announces Results of the Tender Offer for Its 5.75% Notes Due October 1, 2011

Mon, 20 Nov 2006 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) today announced the results of the tender offer for its 5.75% notes due October 1, 2011, which closed at 5:00 p.m. New York Time, on Friday, November 17,

Catholic Medical Mission Board Announces Donation of Lifesaving Pediatric Drugs

Fri, 17 Nov 2006 13:00:00 UT

MANAGUA, Nicaragua--(BUSINESS WIRE)--Lifesaving pediatric antibiotics are on their way to more than 110,000 children in Honduras, Nicaragua, El Salvador, the Dominican Republic and Haiti through the Action for Family

Bristol-Myers Squibb Prices Tender Offer on its 5.75% Notes Due October 1, 2011

Thu, 16 Nov 2006 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) today announced that it priced its offer for its 5.75% notes due October 1, 2011. The offer was priced for settlement on Monday, November 27, 2006 as

Bristol-Myers Squibb Company Announces Promotion of Andrew Bonfield and Elliott Sigal to Executive Vice Presidents

Tue, 14 Nov 2006 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that Andrew Bonfield, chief financial officer, and Elliott Sigal, M.D., Ph.D., chief scientific officer, have been appointed executive

ORENCIA® (abatacept) or REMICADE®(infliximab) Demonstrated Superior Efficacy to Placebo at Six Months With ORENCIA Demonstrating Both Durable Efficacy and a More Favorable Safety Profile Through 12 Months

Tue, 14 Nov 2006 13:00:00 UT

WASHINGTON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a study providing further evidence of the efficacy, safety and durability of response of ORENCIA® (abatacept)

ORENCIA® (abatacept) Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR Pediatric Criteria

Mon, 13 Nov 2006 13:00:00 UT

WASHINGTON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results of the double-blind phase of an ongoing study, which show ORENCIA® (abatacept) demonstrated improvement in children

Two-Year Data for ORENCIA® (abatacept) Demonstrate Continued Efficacy in Adults With Rheumatoid Arthritis

Thu, 9 Nov 2006 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that two-year data from three Phase III pivotal trials demonstrate the long-term efficacy of ORENCIA® (abatacept) in adult

Bristol-Myers Squibb Company Announces Debt Tender Offer

Thu, 9 Nov 2006 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has commenced a cash tender offer to purchase any and all of its outstanding $2.5 billion aggregate principal amount 5.75%

Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer

Mon, 6 Nov 2006 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ:IMCL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced results from two randomized Phase III trials of ERBITUX(R) (cetuximab) in patients with

Study Shows Treatment with BARACLUDEÂ® (Entecavir) Resulted in Greater Viral Load Reductions Compared to Adefovir in Antiviral Naïve Chronic Hepatitis B e-Antigen Positive Patients

Mon, 30 Oct 2006 13:00:00 UT

BOSTON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results of an open-label, randomized study of 65 antiviral naïve chronic hepatitis B e-antigen (HBeAg) positive patients, showing

Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada

Thu, 28 Sep 2006 23:57:00 UT

PRINCETON, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences, Inc. (Nasdaq:GILD) today announced an agreement

PLAVIX® Litigation Settlement Fails to Receive Antitrust Clearance From States Attorneys General

Fri, 28 Jul 2006 12:00:00 UT

PARIS & NEW YORK--(BUSINESS WIRE)--Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb (New York: NYSE: BMY) ("companies") today announced that their agreement, as amended,

Bristol-Myers Squibb Company Reports Financial Results for the Second Quarter and First Half of 2006

Thu, 27 Jul 2006 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the second quarter and six months ended June 30, 2006 and reaffirmed earnings guidance for the full year.

Bristol-Myers Squibb to Announce Results for the Second Quarter of 2006 on July 27

Tue, 18 Jul 2006 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the second quarter of 2006 on Thursday, July 27. During a conference call on July 27 at 10:00 a.m. (ET), financial

U.S. Food and Drug Administration (FDA) Approves ATRIPLA™ (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen For Adults With HIV-1 Infection

Wed, 12 Jul 2006 12:00:00 UT

PRINCETON, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (NASDAQ: GILD) today announced the U.S. Food and Drug Administration (FDA) has granted approval

Bristol-Myers Squibb Names Vicki L. Sato to Board of Directors

Tue, 11 Jul 2006 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that its Board of Directors has elected Vicki L. Sato, Ph.D., to the Board effective today.

FDA Approves SPRYCEL™ (dasatinib) With Two Indications

Wed, 28 Jun 2006 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of SPRYCEL, an oral inhibitor of multiple

Update on Plavix® Litigation Settlement

Sun, 25 Jun 2006 12:00:00 UT

PARIS & NEW YORK & TORONTO--(BUSINESS WIRE)--Sanofi- aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol- Myers Squibb (NYSE: BMY) (the"companies") and Apotex Inc. and Apotex Corp. ("Apotex")

New Two-Year ORENCIA® (abatacept) AIM Data Presented at Annual EULAR Congress

Fri, 23 Jun 2006 12:00:00 UT

AMSTERDAM, Netherlands--(BUSINESS WIRE)--Data presented at the 2006 European League Against Rheumatism (EULAR) annual congress looked at the Bristol-Myers Squibb Company (NYSE: BMY) rheumatoid arthritis (RA) treatment

Bristol-Myers Squibb Announces Dividend

Wed, 14 Jun 2006 12:00:00 UT

Data From a Randomized Phase II Study of Dasatinib or 800 Mg/Day Imatinib- Mesylate (Gleevec®) Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology

Sat, 3 Jun 2006 12:00:00 UT

ATLANTA--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today presented interim data from a randomized Phase II study of the investigational compound dasatinib (140 mg/day) or imatinib (800 mg/day) in

Bristol-Myers Squibb Issues Statement on Oncologic Drugs Advisory Committee Vote in Favor of Investigational Drug Dasatinib

Fri, 2 Jun 2006 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee voted in favor of recommending

Bristol-Myers Squibb To Build New Biologics Facility In Massachusetts

Thu, 1 Jun 2006 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the company intends to build a new large-scale multi-product bulk biologics manufacturing facility in Devens,

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

Wed, 31 May 2006 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--

Bristol-Myers Squibb Company (NYSE: BMY) will host a conference call on June 7 at 8:00 am (ET) to review data presented at the 42nd Annual Meeting of the American Society of Clinical

Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care In Management of Community-Treated Patients with Schizophrenia

Thu, 25 May 2006 12:00:00 UT

TORONTO--(BUSINESS WIRE)--The Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. atypical antipsychotic medicine, aripiprazole, demonstrated significantly greater improvement on the

96-Week Viral Suppression Data From Two Studies Presented for BARACLUDE® (entecavir) in Chronically-Infected Hepatitis B Patients

Tue, 23 May 2006 12:00:00 UT

LOS ANGELES--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today presented 96-week clinical trial data at Digestive Disease Week from two Phase III studies demonstrating that BARACLUDE® (entecavir) led

Bristol-Myers Squibb Announces Discontinuation of Development of Muraglitazar, an Investigational Oral Treatment for Type 2 Diabetes

Thu, 18 May 2006 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has discontinued the development of muraglitazar, a dual alpha/gamma PPAR (peroxisome proliferator-activated receptor)

ABILIFY® (Aripiprazole) Demonstrated Efficacy as Maintenance Therapy In Adults with Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode

Tue, 16 May 2006 12:00:00 UT

'AIM for the B' Public Education Program Seeks to Educate Asian American Community About Chronic Hepatitis B and Importance of Disease Management

Mon, 15 May 2006 12:00:00 UT

PRINCETON, N.J. & DOYLESTOWN, Pa.--(BUSINESS WIRE)--Today, the Hepatitis B Foundation and Bristol-Myers Squibb Company announced the launch of the third-annual "AIM for the B: Awareness, Involvement and Mobilization

U.S. Food and Drug Administration Approves ORENCIA® (abatacept) Supplemental Biologics License Application (sBLA) for Third-Party Manufacturing Facility Lonza Biologics Inc.

Fri, 5 May 2006 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the

Bristol-Myers Squibb Company Reports First Quarter 2006 Financial Results

Thu, 27 Apr 2006 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the first quarter of 2006 and reaffirmed earnings guidance for the full year.

Bristol-Myers Squibb Company Names David I. Johnson President of ConvaTec

Mon, 17 Apr 2006 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that David I. Johnson has been named President, ConvaTec. As president, Mr. Johnson will have responsibility for all aspects of the

Bristol-Myers Squibb to Announce Results For The First Quarter of 2006 on April 27

Mon, 17 Apr 2006 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the first quarter of 2006 on Thursday, April 27. During a conference call on April 27 at 10:30 a.m. (ET), financial

Sanofi-aventis and Bristol-Myers Squibb Announce Agreement to Settle U.S. PLAVIX® Litigation with Apotex Subject to Certain Conditions

Tue, 21 Mar 2006 13:00:00 UT

PARIS & NEW YORK--(BUSINESS WIRE)--Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that they have reached an agreement subject to

Bristol-Myers Squibb Plans to Build Biologics Facility in the U.S.

Wed, 8 Mar 2006 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) said today that it will build its new biologics facility in the United States. At its regularly scheduled meeting on March 7, the company's Board of

The New England Journal of Medicine Reports BARACLUDE™ (entecavir) Demonstrated Benefits Over Lamivudine In Treating Chronically Infected Hepatitis B Patients at 48 Weeks

Wed, 8 Mar 2006 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--BARACLUDE™ (entecavir) demonstrated greater benefit in treating nucleoside-naive chronic hepatitis B patients compared to lamivudine, the most commonly used antiviral therapy for

Bristol-Myers Squibb Announces Dividend

Tue, 7 Mar 2006 13:00:00 UT

FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Dasatinib

Tue, 7 Mar 2006 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the New Drug Application (NDA) for the

FDA Approves ERBITUX® (Cetuximab) for Treatment of Head and Neck Cancer

Wed, 1 Mar 2006 13:00:00 UT

NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved

U.S. Food and Drug Administration Approves EMSAM® (selegiline transdermal system), the First Transdermal Patch for the Treatment of Major Depressive Disorder

Tue, 28 Feb 2006 13:00:00 UT

PRINCETON, N.J. & TAMPA, Fla.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Somerset Pharmaceuticals, Inc., a joint venture between Mylan Laboratories Inc. (NYSE: MYL) and Watson Pharmaceuticals, Inc.,

Swaziland's First Children's HIV/AIDS Medical Center Opens; Building Treatment Capacity in the World's Hardest Hit Country

Fri, 24 Feb 2006 13:00:00 UT

MBABANE, Swaziland--(BUSINESS WIRE)--The first pediatric center dedicated to caring for HIV/AIDS-infected infants and children in Swaziland, the African country with the highest prevalence of AIDS in the world,

Mead Johnson Recalls One Batch of Gentlease™ Powder Infant Formula in 24 Ounce Cans

Tue, 21 Feb 2006 13:00:00 UT

EVANSVILLE, Ind.--(BUSINESS WIRE)--In keeping with our commitment to provide safe and healthy nutritional products, Mead Johnson Nutritionals is initiating a voluntary recall of one batch of Gentlease™ powder

New 48 Week Clinical Trial Data Reported Comparing REYATAZ® (Atazanavir Sulfate), With or Without Ritonavir, in Treatment-Naive Patients

Thu, 9 Feb 2006 13:00:00 UT

DENVER--(BUSINESS WIRE)--Data presented during the Thirteenth Conference on Retroviruses and Opportunistic Infections (CROI) provided results on the virologic and immunologic response and the safety profile of the

Bristol-Myers Squibb Announces Preliminary Approval of Settlement in Shareholder Class Action Litigation

Thu, 9 Feb 2006 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that U.S. District Judge Stanley Chesler has entered preliminary approval of a settlement agreement with plaintiffs in the

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. Announce Availability of 2 mg ABILIFY® (aripiprazole) Tablet and Nonrefrigerated Oral Solution

Tue, 7 Feb 2006 13:00:00 UT

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced two newly available options of ABILIFY® (aripiprazole) -- a 2 mg tablet

Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2005 and Announces EPS Guidance for 2006

Wed, 25 Jan 2006 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the fourth quarter and twelve months ended December 31, 2005 and announced 2006 earnings guidance.

Bristol-Myers Squibb Announces Litigation Reserve

Mon, 23 Jan 2006 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) has recorded a reserve in the amount of $185 million in anticipation of the potential settlement of its consolidated securities class action

Bristol-Myers Squibb to Announce Results for the Fourth Quarter and 12 Months of 2005 on January 25

Wed, 18 Jan 2006 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the fourth quarter and 12 months of 2005 on Wednesday, January 25. During a conference call on January 25 at 10:30 a.m.

Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva(R) (efavirenz) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate)

Mon, 9 Jan 2006 14:10:00 UT

NEW YORK & FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 9, 2006-- Companies Anticipate Filing New Drug Application in Second Quarter of 2006

Bristol-Myers Squibb Company Announces Submission of ORENCIA® (abatacept) Supplemental Biologics License Application to the U.S. Food and Drug Administration

Tue, 3 Jan 2006 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has completed submission of the supplemental Biologics License Application (sBLA) to the U.S. Food and Drug

Study Reported in JAMA Concludes That High Level of Hepatitis B Virus in Patients With Chronic Hepatitis B Infection Predicts Increased Risk For Liver Cancer

Tue, 3 Jan 2006 13:00:00 UT

TAIPEI, Taiwan & PRINCETON, N.J.--(BUSINESS WIRE)--Chronic hepatitis B patients with high levels of circulating hepatitis B virus (HBV) appear to be at increased risk of developing liver cancer (specifically,

Bristol-Myers Squibb Submits New Drug Application for Dasatinib

Wed, 28 Dec 2005 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Today, Bristol-Myers Squibb Company (NYSE: BMY) announced that the Company has completed the rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug

U.S. Food and Drug Administration Approves ORENCIA® (abatacept) for the Treatment of Rheumatoid Arthritis

Fri, 23 Dec 2005 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved ORENCIA® (abatacept), the first selective modulator of a

Bristol-Myers Squibb Statement on Muraglitazar, an Investigational Oral Treatment for Type 2 Diabetes

Thu, 22 Dec 2005 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--As previously disclosed, Bristol-Myers Squibb Company (NYSE: BMY) agreed to begin discussions with Merck & Co., Inc. to terminate the collaborative agreement for muraglitazar, the

Crohn's Patient Robert Hill To Scale Antarctic Summit For Intestinal Disease Awareness

Tue, 20 Dec 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Crohn's disease patient Robert (Rob) Hill announced today his team's plans to summit Vinson Massif, Antarctica's tallest mountain, in January 2006. The expedition, sponsored by ConvaTec, a

More Than 100,000 People Unite To Support AIDS Prevention And Care Programs Through Bristol-Myers Squibb 2005 World AIDS Day Campaign

Fri, 16 Dec 2005 13:00:00 UT

WASHINGTON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today presented a $100,000 donation to the National AIDS Fund to provide funding for AIDS service organizations across the United States. The

Plavix® Recommended As Effective Cardiovascular Risk Reduction Treatment For Patients With Established Peripheral Arterial Disease

Tue, 13 Dec 2005 13:00:00 UT

BRIDGEWATER, N.J. & PRINCETON, N.J.--(BUSINESS WIRE)--Recently, the American College of Cardiology (ACC) and the American Heart Association (AHA) announced the first-ever U.S. guidelines for the diagnosis and treatment

Bristol-Myers Squibb Updates The Investment Community On The Continued Execution Of The Company's Strategy

Mon, 12 Dec 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) is presenting an update on its progress toward completing the strategic transformation of its business, to achieve sales and earnings growth beginning

Bristol-Myers Squibb Company To Webcast December 12 Business Update

Mon, 12 Dec 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will provide a business update to the investment community on Monday, December 12 from 1 p.m to 4:30 p.m. (EST).

Bristol Myers Squibb Company Announces Dividend

Tue, 6 Dec 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of $0.28 per share on the $0.10 par value Common Stock of the corporation and an

Bristol-Myers Squibb Promotes John E. Celentano To President Of Health Care Group

Fri, 2 Dec 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has promoted John E. Celentano to president, Health Care Group. In this new assignment, Celentano will have responsibility for

First Children's HIV/AIDS Medical Center Opens in Lesotho

Thu, 1 Dec 2005 13:00:00 UT

MASERU, Lesotho--(BUSINESS WIRE)--The first medical center dedicated to caring for HIV/AIDS-infected infants and children in Lesotho, operated by Baylor College of Medicine, Houston, Texas in partnership with the

48-Week Clinical Trial Data Provides Information Regarding Switching From An Existing Protease Inhibitor-Based Regimen To A Reyataz® -Based Regimen

Fri, 18 Nov 2005 13:00:00 UT

DUBLIN, Ireland--(BUSINESS WIRE)--In a 48-week study presented today at the 10th European AIDS Conference (EACS), 7 percent of HIV-1- infected patients who switched from a stable, protease inhibitor-based (PI) anti-HIV

Crohn's & Colitis Foundation Of America And ConvaTec Announce 2005 Great Comebacks Recipients

Fri, 18 Nov 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--The Crohn's & Colitis Foundation of America (CCFA) and ConvaTec, the world's leading ostomy manufacturer and a leading wound care company, today announced the 2005 recipients of the 21st

Long-Term Phase III Data On Investigational Biologic Orencia® Presented During Late-Breaking Session Of American College Of Rheumatology Meeting

Wed, 16 Nov 2005 13:00:00 UT

SAN DIEGO, Calif.--(BUSINESS WIRE)--New clinical data with Orencia® (abatacept) showed that of the 168 subjects who completed 18 months of an open-label extension phase of the ATTAIN study, 56.7 percent achieved

Baraclude™ Two-Year Data Analysis Did Not Detect Emergence Of Resistance In Nucleoside-Naïve Chronic Hepatitis B Patients

Mon, 14 Nov 2005 13:00:00 UT

SAN FRANCISCO--(BUSINESS WIRE)--Data planned for presentation at the 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) demonstrated no virologic rebounds due to resistance through

Mead Johnson Nutritionals Donates $100,000 To Support Local Tornado Victims

Tue, 8 Nov 2005 15:00:00 UT

EVANSVILLE, Indiana--(BUSINESS WIRE)--Mead Johnson Nutritionals announced today that it will donate $100,000 to the local chapter of the American Red Cross to help support victims of the recent tornado in the

First Wave Of "Pediatric AIDS Corps" Heads To Africa To "Treat And Train"

Tue, 1 Nov 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--They trained to keep children healthy. Now they will take on the toughest of health challenges -- treating children with AIDS and training medical workers in parts of the world where

Merck and Bristol-Myers Squibb License New AIDS Drugs to IPM for Development as Microbicides to Protect Women from HIV

Mon, 31 Oct 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--In a first-of-its-kind joint announcement, two of the world's leading pharmaceutical companies, Merck & Co., Inc. and Bristol-Myers Squibb have each announced today that they have signed

FDA Accepts Erbitux® sBLA Submission For The Treatment Of Squamous Cell Carcinoma Of The Head And Neck And Grants Priority Review

Mon, 31 Oct 2005 13:00:00 UT

Bristol-Myers Squibb Company Reports Financial Results for the Third Quarter and First Nine Months of 2005, Reflecting Ongoing Investments in Strategy Aimed at Delivering Sustainable Growth

Fri, 28 Oct 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the quarter and nine months ended September 30, 2005 and provided further earnings guidance for the full year.

Bristol-Myers Squibb Company To Announce Results For The Third Quarter And First Nine Months Of 2005 On October 28

Fri, 28 Oct 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter and first nine months of 2005 on Friday, October 28. During a conference call on October 28 at 9 a.m.

Pediatric HIV/AIDS Medical Centers to be Built in African Nations of Lesotho and Swaziland

Thu, 27 Oct 2005 12:00:00 UT

JOHANNESBURG, South Africa--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY), New York; Baylor College of Medicine, Houston, Texas; and the governments of Lesotho and Swaziland announced that medical centers

Bristol-Myers Squibb Statement On Muraglitazar, An Investigational Oral Treatment For Type 2 Diabetes

Thu, 27 Oct 2005 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--As previously disclosed, on October 18, 2005, the U.S. Food and Drug Administration (FDA) issued an approvable letter for muraglitazar, Bristol-Myers Squibb Company's (NYSE: BMY)

The Gallery At Bristol-Myers Squibb Portrays Changing Face Of AIDS In Africa

Tue, 25 Oct 2005 12:00:00 UT

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--The Gallery at Bristol-Myers Squibb today opened a special photo exhibit: "A Time for Hope: Changing the Face of AIDS in Africa." The exhibit illustrates not only the devastation

Distinguished Achievement Awards Go To Seven Leading Researchers For Groundbreaking Discoveries; $6.5 Million In No-Strings-Attached Grants Support 13 Scientists For Cutting Edge Biomedical Research Across Three Continents

Thu, 20 Oct 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Honoring groundbreaking achievements as well as supporting cutting-edge research are the themes of this year's Bristol-Myers Squibb Company (NYSE:BMY) Freedom to Discover- Distinguished

Bristol-Myers Squibb And Merck Joint Statement On Regulatory Status Of Pargluva™, An Investigational Oral Treatment For Type 2 Diabetes

Tue, 18 Oct 2005 12:00:00 UT

PRINCETON, N.J. & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Merck & Co., Inc. (NYSE: MRK) jointly announced today that the U.S. Food and Drug Administration (FDA)

Survey Provides Insights Into Factors Influencing Drug Adherence Among HIV Patients

Tue, 18 Oct 2005 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Results were released today from one of the largest national surveys on medication adherence issues for people living with HIV/AIDS. According to patients surveyed, adherence to HIV

Bristol-Myers Squibb To Host 2005 Susan G. Komen New Jersey Race For The Cure

Sun, 16 Oct 2005 12:00:00 UT

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY), a world leader in cancer therapies, will host over 25,000 people from New Jersey communities at the company's Lawrenceville campus for the

Lance Armstrong Leads the Bristol-Myers Squibb Tour of Hope(TM) To Raise Awareness About the Promise of Cancer Research

Tue, 11 Oct 2005 12:00:00 UT

LOS ANGELES--(BUSINESS WIRE)--A team of cyclists led by cancer survivor and Tour de France champion Lance Armstrong will embark on a week- long ride from Los Angeles to Washington, DC on the Bristol-Myers Squibb Tour

Bristol-Myers Squibb Names Richard Willard Senior Vice President And General Counsel

Tue, 11 Oct 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that Richard K. Willard has joined the company as senior vice president and general counsel. He succeeds John L. McGoldrick, who will

Bristol-Myers Squibb Invites Others To Join In Expansion Of Pediatric AIDS Corps In Africa

Tue, 27 Sep 2005 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--At an awards dinner in Washington D.C. tomorrow night, Bristol-Myers Squibb Company (NYSE: BMY) Chief Executive Officer Peter R. Dolan will invite other members of the Global Business

Bristol-Myers Squibb Company Reorganizes Operating Units, Promoting Lamberto Andreotti To Executive Vice President And President, Worldwide Pharmaceuticals

Tue, 20 Sep 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) announced today that it has reorganized its operating units, consolidating its global pharmaceutical operations under the leadership of Lamberto Andreotti,

Bristol-Myers Squibb Company Announces Planned Departure Of Donald Hayden, Executive Vice President And President, Americas

Tue, 20 Sep 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb announced today that Donald J. Hayden, Jr., executive vice president and president, Americas, has decided to begin transitioning out of the company in order to pursue his

Bristol-Myers Squibb Tour of Hope™ Team Joins Lance Armstrong To Kick Off 3,300-Mile Cycling Journey to Raise Awareness about Cancer Clinical Trials

Mon, 19 Sep 2005 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--The Bristol-Myers Squibb Tour of Hope™ Team will embark on a nine-day, 3,300-mile cross-country bicycle relay that departs from Scripps Green Hospital in San Diego, California,

Bristol-Myers Squibb Announces Dividend

Tue, 13 Sep 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of twenty-eight cents ($.28) per share on the $0.10 par value Common Stock of the

Bristol-Myers Squibb Names Louis J. Freeh To Board Of Directors

Tue, 13 Sep 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that its Board of Directors has elected Louis J. Freeh, Vice Chairman of MBNA America Bank, N.A., to the Board. His appointment is

Bristol-Myers Squibb Named One Of The 10 Best Companies For Working Mothers

Mon, 12 Sep 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb was named today as one of the 10 Best Companies for Working Mothers by Working Mother magazine. This is the eighth consecutive year that the company has been listed in

Bristol-Myers Squibb And Merck Joint Statement On FDA Advisory Committee Vote On Pargluva™ , An Investigational Oral Treatment For Type 2 Diabetes

Fri, 9 Sep 2005 12:00:00 UT

PRINCETON, N.J. & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: ) and Merck & Co., Inc. (NYSE: MRK) jointly announced today that the U.S. Food and Drug Administration's (FDA) Endocrinologic

Bristol-Myers Squibb Statement On FDA Advisory Committee Vote On Orencia® , An Investigational Selective Modulator Of T-Cell Co-Stimulation For Rheumatoid Arthritis

Tue, 6 Sep 2005 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee unanimously (7-0) recommended approval of

Bristol-Myers Squibb Company Closes Previously Announced Sale Of U.S. And Canadian Consumer Medicines Business

Wed, 31 Aug 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported that it has completed the previously announced sale of its U.S. and Canadian Consumer Medicines business to Novartis AG (NYSE: NVS).

ImClone Systems Incorporated And Bristol-Myers Squibb File Supplemental Biologics License Application For Erbitux® For Treatment Of Head And Neck Cancer

Tue, 30 Aug 2005 12:00:00 UT

NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that ImClone Systems has submitted a supplemental Biologics License

Bristol-Myers Squibb Supports Community Programs In Mercer County

Tue, 23 Aug 2005 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) today announced grants totaling more than $174,000 to support non-profit community organizations in Mercer County. The grants provide support for

Walter C. Willett, M.D., Dr. P.H., Wins Nutrition Research Award

Mon, 15 Aug 2005 12:00:00 UT

EVANSVILLE, Ind.--(BUSINESS WIRE)--Walter C. Willett, M.D., Dr. P.H., Chairman of the Department of Nutrition and Fredrick John Stare Professor of Epidemiology and Nutrition at the Harvard School of Public Health, and

New Enfamil® Gentlease™ Lipil® Now Available For Babies With Fussiness Or Gas

Wed, 10 Aug 2005 12:00:00 UT

EVANSVILLE, Ind.--(BUSINESS WIRE)--New Enfamil Gentlease LIPIL infant formula is now available, making it the first and only formula in the U.S. that combines partially broken down whey and casein milk proteins,

Bristol-Myers Squibb Announces Financial Results For The Second Quarter And First Half Of 2005, With Businesses On Plan, Led By Pharmaceutical Growth Drivers

Thu, 28 Jul 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the quarter and six months ended June 30, 2005 and provided further earnings guidance for the full year.

Bristol-Myers Squibb Company To Announce Results for the Second Quarter And First Half Of 2005 On July 28

Thu, 28 Jul 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the second quarter and first half of 2005 on Thursday, July 28. During a conference call on July 28 at 9 a.m. (ET),

Christine Petit, M.D., Ph.D., Head Of An Institut Pasteur-Inserm Unit, Receives Bristol-Myers Squibb Neuroscience Research Award

Wed, 27 Jul 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Christine Petit, M.D., Ph.D., head of the Unit for Genetics of Sensory Deficits at the Institut Pasteur in Paris, head of Inserm Unit 587, and professor and chair of genetics and cellular

Stephen C. Harrison, Ph.D., Of Harvard Medical School, Wins Bristol-Myers Squibb Infectious Diseases Research Award

Tue, 26 Jul 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Stephen C. Harrison, Ph.D., professor of biological chemistry and molecular pharmacology, professor of pediatrics, and director of the Center for Molecular and Cellular Dynamics of Harvard

ConvaTec's Bolton And Co-Authors Receive JWOCN 2005 Manuscript Award

Thu, 21 Jul 2005 12:00:00 UT

SKILLMAN, N.J.--(BUSINESS WIRE)--The Journal of Wound, Ostomy and Continence Nursing presented its 2005 Manuscript Award to Laura Bolton, Ph.D., Director of Scientific Affairs and Medical Communications, ConvaTec, and

ConvaTec Launches Aloe Vesta® Protective Barrier Spray With State-of-the-Art Delivery System

Mon, 11 Jul 2005 12:00:00 UT

SKILLMAN, N.J.--(BUSINESS WIRE)--ConvaTec, a world leader in ostomy and wound and skin care, has launched its new Aloe Vesta® Protective Barrier Spray featuring an innovative delivery system. Aloe Vesta Protective

Bristol-Myers Squibb Company, Baylor College Of Medicine To Establish Pediatric Aids Corps For Africa

Mon, 27 Jun 2005 12:00:00 UT

HOUSTON & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company, New York (NYSE: BMY) and Baylor College of Medicine, Houston, today announced a groundbreaking multi-part program to provide medical care for African

Bristol-Myers Squibb Supports Local Emergency Services

Fri, 24 Jun 2005 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Recognizing that June is National Safety Month, Bristol-Myers Squibb Company (NYSE: BMY) today announced $123,000 in contributions for New Jersey emergency services. The contributions

Bristol-Myers Squibb Company Signs Manufacturing Agreement With Celltrion

Tue, 21 Jun 2005 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has completed an agreement with Celltrion, Inc. for Celltrion to manufacture biologic products being developed by

Bristol-Myers Squibb Tour of Hope™ Announces Team of Cancer Advocates To Join Lance Armstrong In Cross Country Journey In Support of Cancer Research

Mon, 20 Jun 2005 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--A team of 24 cancer survivors, caregivers, researchers, nurses and physicians has been selected to ride from San Diego to Washington, D.C. this fall as members of the Bristol-Myers

Salih J. Wakil, Ph.D., Of Baylor College Of Medicine, Wins Bristol-Myers Squibb Metabolic Research Award

Mon, 20 Jun 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Salih J. Wakil, Ph.D., L.T. Bolin Professor and chairman of the Verna and Marrs McLean Department of Biochemistry and Molecular Biology at Baylor College of Medicine, Houston, Texas, has been

Bristol-Myers Squibb Announces Dividend

Wed, 15 Jun 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE: BMY) today declared a quarterly dividend of twenty-eight cents ($.28) per share on the $.10 par value Common Stock of the

Bristol-Myers Squibb Announces Agreement With The U.S. Attorney's Office In New Jersey

Wed, 15 Jun 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has resolved the investigation by the U.S. Attorney's Office in New Jersey relating to wholesaler inventory and various

James D. Robinson III Elected Non-Executive Chairman Of The Board Of Bristol-Myers Squibb; Peter R. Dolan Continues As CEO

Wed, 15 Jun 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) today announced that its Board has elected director James D. Robinson III, 69, as its non-executive Chairman. Peter R. Dolan, 49, who has served as the

Phase III And II Data For Investigational Medicine Pargluva™ Highlighted In Late-Breaking Presentation At Annual Scientific Sessions Of The American Diabetes Association

Sun, 12 Jun 2005 12:00:00 UT

SAN DIEGO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Merck & Co, Inc. (NYSE: MRK) announced results from both a Phase III active-controlled study and a long-term Phase II dose-ranging study for

New Phase III Efficacy Data On Investigational Biologic Abatacept Presented At EULAR Meeting

Thu, 9 Jun 2005 12:00:00 UT

VIENNA, Austria--(BUSINESS WIRE)--The investigational drug abatacept inhibited the progression of joint damage in subjects with active rheumatoid arthritis (RA), independent of baseline clinical, biochemical or

Bristol Myers Squibb Announces Settlement With Opt Out Plaintiffs In Securities Class Action Litigation

Wed, 1 Jun 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has reached an agreement to settle the four lawsuits brought against it in New York State Supreme Court by plaintiffs who

New Investigational Data Using Intramuscular Administration Of Aripiprazole In Patients With Acute Bipolar Mania And Schizophrenia

Wed, 25 May 2005 12:00:00 UT

ATLANTA--(BUSINESS WIRE)--In two double-blind, randomized, multicenter studies reported this week at the 158thAnnual Meeting of the American Psychiatric Association, data were presented on the investigational use of

New Study Shows Investigational Compound Muraglitazar Significantly Lowered Blood Glucose Levels As Measured By A1C Reduction In Patients With Type 2 Diabetes

Fri, 20 May 2005 12:00:00 UT

PRINCETON, N.J. & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Results from a Phase III study presented today at the 14th Annual Meeting of the American Association of Clinical Endocrinologists (AACE) in Washington, D.C.

Lance Armstrong And Cancer Community Seek Cyclists For 2005 Bristol-Myers Squibb Tour of Hope™ National Team

Fri, 20 May 2005 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Cancer survivor and six-time Tour de France champion Lance Armstrong and Bristol-Myers Squibb announced today that applications are being accepted for the 2005 Bristol-Myers Squibb

Phase II Clinical Study Of MDX-010/MDX-1379 Combination Shows Durable Responses In Patients With Metastatic Melanoma

Fri, 20 May 2005 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Medarex, Inc. (Nasdaq: MEDX) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that complete or partial responses in seven of 56 patients with metastatic melanoma showed

Mead Johnson Nutritionals And Bristol-Myers Squibb Foundation Provide Over $725,000 To Local Charitable Organizations

Thu, 19 May 2005 12:00:00 UT

EVANSVILLE, Ind.--(BUSINESS WIRE)--Mead Johnson Nutritionals and the Bristol-Myers Squibb Foundation will provide over $725,000 to local charitable organizations in 2005. A total of 40 not-for-profit agencies will be

Erbitux® Scientific Data In Several Tumor Types Presented At ASCO Annual Meeting

Mon, 16 May 2005 12:00:00 UT

ORLANDO, Fla.--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of several clinical studies of Erbitux® (Cetuximab), an IgG1

Bristol-Myers Squibb Closes Previously Announced Sale Of Its OTN Distribution Business To One Equity Partners LLC

Wed, 11 May 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has completed the sale of its Oncology Therapeutics Network (OTN) distribution business to One Equity Partners LLC.

The Gallery At Bristol-Myers Squibb's Spring Exhibition Offers Contemporary Paintings Of The New Jersey Shore

Tue, 10 May 2005 12:00:00 UT

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--The Gallery at Bristol-Myers Squibb today opened its spring exhibition, "Canvassing the Coast: Contemporary Paintings Inspired by the New Jersey Shore." The show will remain on

Bristol-Myers Squibb Revises Certain Financial Information With Filing Of Its First Quarter 2005 Form 10-Q

Mon, 9 May 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) filed with the Securities and Exchange Commission today its 2005 first quarter Form 10-Q that revises certain financial information relating to

"Aim For The B" Targets Need To Increase Education And Awareness For Chronic Hepatitis B -- Public Education Program to Take Place During "National Hepatitis B Awareness Week"

Mon, 9 May 2005 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--In recognition of the need to increase education and awareness for chronic hepatitis B, the Hepatitis B Foundation and Bristol-Myers Squibb Company are partnering to host "AIM for the

Bristol-Myers Squibb To Announce First Quarter Results For 2005 On April 28, 2005

Thu, 28 Apr 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce first quarter results for 2005 on Thursday, April 28. During a conference call on that day at 9 a.m. (ET), financial information will be

Bristol-Myers Squibb Reports First Quarter 2005 Results In Line With Expectations And Increased Investment In Research And Growth Products

Thu, 28 Apr 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the first quarter of 2005, in line with expectations, detailed recent pipeline achievements and reaffirmed its

Bristol-Myers Squibb Announces Settlement Of Derivative Litigation Against Current And Former Officers And Directors

Wed, 27 Apr 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. District Court in the Southern District of New York preliminarily approved a settlement of the derivative claims brought

Contemporary New Jersey Shore Paintings To Be Featured At The Gallery At Bristol-Myers Squibb

Mon, 25 Apr 2005 12:00:00 UT

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--The Gallery at Bristol-Myers Squibb this spring will present "Canvassing the Coast: Contemporary Paintings Inspired by the New Jersey Shore" -- an exhibition of 49 paintings by

Together Rx Access™ Launches Ads To Encourage Americans With No Prescription Drug Coverage To Enroll In Savings Program

Mon, 25 Apr 2005 12:00:00 UT

ALEXANDRIA, Va.--(BUSINESS WIRE)--Together Rx Access, LLC today launched national advertising to generate awareness and build enrollment in the new Together Rx Access- prescription savings program among as many

Bristol-Myers Squibb Medical Imaging Awarded Three-Year Contract For DEFINITY® By Premier

Thu, 21 Apr 2005 12:00:00 UT

N. BILLERICA, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Medical Imaging today announced that Premier Purchasing Partners, L.P., the group purchasing division of Premier Inc., has awarded Bristol-Myers Squibb Medical

ImClone Systems And Bristol-Myers Squibb Announce Amended Timeline For Erbitux® Supplemental Biologics License Application Filing In Head And Neck Cancer

Tue, 12 Apr 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that they intend to file a supplemental Biologics License Application (sBLA) to seek

Bristol-Myers Squibb Joins National Program To Help Uninsured Americans Get The Prescription Medications They Need

Tue, 5 Apr 2005 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced its participation in the Partnership for Prescription Assistance, the largest-ever private-sector program to help patients who lack

Bristol-Myers Squibb Announces Results Of Tender Offer And Intention To Redeem All Remaining 2006 Notes

Fri, 1 Apr 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) today announced the results of its cash tender offer to purchase any and all of its outstanding $2.5 billion aggregate principal amount 4.75% Notes due 2006,

Bristol Myers Squibb Prices Tender Offer

Wed, 30 Mar 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) today announced that it has priced its cash tender offer to purchase any and all of its outstanding $2.5 billion aggregate principal amount 4.75 percent Notes

Corgentech And Bristol-Myers Squibb Announce Results From Edifoligide Phase 3 Trial for Coronary Artery Bypass Graft Failure

Wed, 30 Mar 2005 13:00:00 UT

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Corgentech Inc. (Nasdaq: CGTK), and Bristol-Myers Squibb Company (NYSE: BMY) today announced top-line results from PREVENT IV, a Phase 3 clinical trial

U.S. Food And Drug Administration Approves Baraclude™ For Treatment Of Chronic Hepatitis B

Tue, 29 Mar 2005 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved Baraclude™ (entecavir). Baraclude is indicated for the

Mark T. Keating, M.D., Wins Bristol-Myers Squibb Cardiovascular Research Award

Tue, 29 Mar 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Mark T. Keating, M.D., professor of cell biology and pediatrics at Harvard Medical School, professor of cardiology at Children's Hospital Boston and an investigator of the Howard Hughes

Bristol Myers Squibb Announces Debt Tender Offer

Wed, 23 Mar 2005 13:00:00 UT

Bristol-Myers Squibb Extends Assistance To State AIDS Drug Assistance Programs

Tue, 22 Mar 2005 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced the company will extend its relief efforts for two more years to the state-administered AIDS Drug Assistance Programs (ADAPs)

Bristol-Myers Squibb Statement On FDA Advisory Committee Vote On BARACLUDE™, An Investigational Oral Antiviral Agent For Chronic Hepatitis B

Fri, 11 Mar 2005 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee unanimously recommended approval of

Mead Johnson Marks 100th Anniversary With $250,000 Gift To Greenway Project

Thu, 10 Mar 2005 12:00:00 UT

EVANSVILLE, Ind.--(BUSINESS WIRE)--Mead Johnson Nutritionals, a world leader in infant and children's nutrition, is commemorating its 100th anniversary by donating $250,000 to the City of Evansville Parks Foundation to

Medarex and Bristol-Myers Squibb Announce Complete and Partial Responses Observed in Phase I/II Clinical Study of MDX-010 in Combination with Il-2

Mon, 7 Mar 2005 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Medarex, Inc. (Nasdaq: MEDX - News) and Bristol-Myers Squibb (NYSE: BMY - News) announced today results of an early clinical study with the investigational fully human anti-CTLA-4

ABILIFY® Granted Approval For New Indication

Mon, 7 Mar 2005 12:00:00 UT

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) approved ABILIFY®

Bristol-Myers Squibb Supports Area Robotics Teams In Multinational Science, Technology And Engineering Competition

Thu, 3 Mar 2005 12:00:00 UT

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced grants totaling more than $67,500 to support robotics teams at five central New Jersey school districts competing in the

Bristol-Myers Squibb Announces Dividend

Tue, 1 Mar 2005 13:00:00 UT

Alfred G. Knudson Jr., M.D., Ph.D., Of Fox Chase Cancer Center, Wins Bristol-Myers Squibb Cancer Research Award

Thu, 24 Feb 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Alfred G. Knudson Jr., M.D., Ph.D., a Fox Chase Cancer Center Distinguished Scientist and senior advisor to the president of Fox Chase in Philadelphia, Pennsylvania, has been selected to

Bristol-Myers Squibb Makes Gift Of Science To Toddlers And Preschoolers

Thu, 24 Feb 2005 13:00:00 UT

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today unveiled a preschool curriculum designed to enhance children's exploratory skills by making science learning fun for some of the

The Gallery At Bristol-Myers Squibb Features Art Using Symbolic Expressions

Mon, 14 Feb 2005 13:00:00 UT

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--The Gallery at Bristol-Myers Squibb in Lawrenceville today opened Signs and Symbols: Journey of the Spirit, the opening exhibit for 2005. The exhibit will remain on view through

Mead Johnson Nutritionals Celebrates 100 Years Of Innovation In Infant And Children's Nutrition

Thu, 10 Feb 2005 13:00:00 UT

EVANSVILLE, Ind.--(BUSINESS WIRE)--Mead Johnson Nutritionals is celebrating its 100th anniversary in 2005. The company, recognized around the world as a leader in pediatric nutrition, looks to build on its rich

Bristol-Myers Squibb Announces Fourth Quarter And Twelve Months Sales And Earnings For 2004

Thu, 27 Jan 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reported net earnings from continuing operations of $139 million on sales from continuing operations of $5.2 billion for the fourth quarter of

Bristol-Myers Squibb To Announce Fourth Quarter And 12 Months Results For 2004 On January 27, 2005

Thu, 27 Jan 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce fourth quarter earnings and 12 months sales and earnings for 2004 on Thursday, January 27. During a conference call on that day at 10:30

Bristol-Myers Squibb To Honor Locals For Community Service At Martin Luther King, Jr. Tribute

Mon, 17 Jan 2005 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will recognize two individuals and one organization from the New Brunswick area for their commitment to community service, during the company's

Thousands Of Rural South African Residents Mobilize To Fight HIV/AIDS

Fri, 14 Jan 2005 13:00:00 UT

DRIEFONTEIN, South Africa--(BUSINESS WIRE)--A crowd expected to exceed 5,000 residents of the rural KwaZulu Natal Province gathered today in a "community mobilization" to fight HIV/AIDS and to formally mark the

Sod-turning Ceremony Marks Start Of Construction Of First Pediatric HIV/AIDS Medical Center In Swaziland

Thu, 13 Jan 2005 13:00:00 UT

MBABANE, Swaziland--(BUSINESS WIRE)--With the Right Honorable Absalom Themba Dlamini, prime minister of Swaziland, presiding, a sod-turning ceremony here today marked the start of construction of the first pediatric

Bristol-Myers Squibb and Medarex Global Development and Commercialization Collaboration for MDX-010 Becomes Effective

Thu, 13 Jan 2005 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (Nasdaq: MEDX) today announced that the global development and commercialization collaboration agreement, previously

Bristol-Myers Squibb Plans To Divest U.S. And Canadian Consumer Medicines Business

Wed, 12 Jan 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that it intends to divest its U.S. and Canadian consumer medicines business. Over the coming weeks, the company will contact

New Together Rx Access™ Card Offers Americans With No Prescription Drug Coverage Savings At The Pharmacy Counter

Tue, 11 Jan 2005 13:00:00 UT

WASHINGTON--(BUSINESS WIRE)--Approximately 36 million uninsured Americans will be eligible to receive meaningful savings on a wide range of brand-name and generic prescription products through the Together Rx

FDA Approves Oral Solution Formulation Of Abilify®

Tue, 4 Jan 2005 13:00:00 UT

PRINCETON, N.J. & TOKYO, Japan--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced that the companies received approval from the U.S. Food and Drug

Bristol-Myers Squibb Names James M. Cornelius To Board Of Directors

Mon, 3 Jan 2005 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that its Board of Directors has elected James M. Cornelius, non-executive chairman of Guidant Corporation, to the Board. His

Results From Two Major Clinical Trials Presented At ACC

Fri, 31 Dec 2004 13:00:00 UT

PARIS & PRINCETON, N.J.--(BUSINESS WIRE)--Results of two major clinical trials showed that the antiplatelet agent clopidogrel, given on top of standard therapy, provided significant benefits to patients with acute

Bristol-Myers Squibb Provides Regulatory Update For Muraglitazar And Abatacept

Thu, 23 Dec 2004 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the company submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for muraglitazar, an

Bristol-Myers Squibb And Somerset Pharmaceuticals Enter Into Agreement To Distribute And Commercialize EMSAM®, Investigational Transdermal Treatment For Major Depressive Disorder

Wed, 22 Dec 2004 13:00:00 UT

NEW YORK & TAMPA, Fla.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Somerset Pharmaceuticals, Inc., a joint venture between Mylan Laboratories Inc. (NYSE: MYL) and Watson Pharmaceuticals, Inc. (NYSE:

Bristol-Myers Squibb And Gilead Sciences Establish U.S. Joint Venture To Develop And Commercialize Fixed-Dose Combination Of Three HIV Medicines

Mon, 20 Dec 2004 13:00:00 UT

NEW YORK & FOSTER CITY, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of a joint venture to develop and commercialize the fixed-dose

Bristol-Myers Squibb To Sell Oncology Therapeutics Network

Tue, 14 Dec 2004 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) has signed a definitive agreement to sell its Oncology Therapeutics Network (OTN) unit to One Equity Partners LLC. It is expected that this

Bristol-Myers Squibb And Medarex Provide Additional Information To FTC

Fri, 10 Dec 2004 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (Nasdaq: MEDX) today announced that the Federal Trade Commission (FTC) has requested an extension of the review period in

Bristol-Myers Squibb Announces Intent To Pursue FDA Approval Of Pravachol® As An OTC Cholesterol-Lowering Therapy

Fri, 10 Dec 2004 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that it intends to pursue U.S. Food and Drug Administration (FDA) approval for an over-the-counter (OTC) version of

Bristol-Myers Squibb Supports New Jersey Arts And Culture

Wed, 8 Dec 2004 13:00:00 UT

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) today announced more than $255,000 in contributions to fund art and cultural institutions which enrich the lives of New Jerseyans.

ConvaTec Launches Advanced Fecal Incontinence Management System

Tue, 7 Dec 2004 13:00:00 UT

SKILLMAN, N.J.--(BUSINESS WIRE)--ConvaTec, a Bristol-Myers Squibb (NYSE:BMY) company, launched its new Flexi-Seal® Fecal Management System (FMS) for patients with episodic fecal incontinence in U.S. markets in

Bristol-Myers Squibb Announces Dividend

Tue, 7 Dec 2004 13:00:00 UT

Corgentech And Bristol-Myers Squibb Announce Results From Edifoligide Phase 3 Trial For Peripheral Bypass Graft

Mon, 6 Dec 2004 13:00:00 UT

Bristol-Myers Squibb Launches ChoiceDM™ A1C Home Test -- First At-Home Test To Measure Long Term Blood Sugar Control

Mon, 6 Dec 2004 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY), today announced the availability of the ChoiceDM™ A1C Home Test, the only over-the-counter test to measure glycated hemoglobin (HbA1c or A1C)

Phase I Study Results Of Investigational Agent BMS-354825 In Patients With Imatinib-Resistant Or Intolerant Chronic Myelogenous Leukemia Presented At The 46th Annual Meeting Of The American Society Of Hematology

Sun, 5 Dec 2004 13:00:00 UT

SAN DIEGO--(BUSINESS WIRE)--Phase I data presented today at the 46th annual meeting of the American Society of Hematology showed that patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML)

'Tis the Season for Giving: Enfamil® LIPIL® Wants to Send Your Baby to College

Thu, 2 Dec 2004 13:00:00 UT

EVANSVILLE, Ind.--(BUSINESS WIRE)--According to findings in the Enfamil® LIPIL® Smart Development Survey, eighty-eight percent of new mothers feel that a college education is crucial to their child's ability

Bristol-Myers Squibb Invites Yahoo!'s Global Audience To Shine A Light On The HIV/AIDS Crisis On World AIDS Day

Wed, 1 Dec 2004 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) is working with Yahoo! to raise awareness of the global HIV/AIDS crisis through the "Light to Unite" initiative on World AIDS Day. The company will

Bristol-Myers Squibb Invites Yahoo!'s Global Audience to Shine a Light on the HIV/AIDS Crisis on World AIDS Day

Tue, 30 Nov 2004 13:00:00 UT

Bristol-Myers Squibb Showcases Pipeline at Research and Development Overview Meeting

Wed, 17 Nov 2004 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) said today at a meeting with the investment community, which was web cast, that the company is on track to submit three regulatory submissions for

Bristol-Myers Squibb to Host Research and Development Overview with Financial Analysts on November 17, 2004

Thu, 11 Nov 2004 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) is hosting a meeting for the investment community at 8 a.m. on Wednesday, November 17 to provide a comprehensive update on the company's research and

Bristol-Myers Squibb Foundation and China Foundation for Hepatitis Prevention and Control Collaborate to Fight One of China's Most Pressing Health Problems

Mon, 1 Nov 2004 13:00:00 UT

BOSTON--(BUSINESS WIRE)--Bristol-Myers Squibb Foundation and the China Foundation for Hepatitis Prevention and Control (CFHPC) announce the results of a collaborative grassroots education and vaccination program

UPDATE: Investigational Hepatitis B Agent entecavir Demonstrated Statistically Significant Improvement Over lamivudine in Chronically Infected Hepatitis B Patients

Mon, 1 Nov 2004 13:00:00 UT

BOSTON--(BUSINESS WIRE)--According to data to be presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), the Bristol-Myers Squibb Company (NYSE: BMY) investigational

Bristol-Myers Squibb Announces Third Quarter and Nine Months Sales and Earnings for 2004

Fri, 29 Oct 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported net earnings of $758 million on sales of $5.4 billion for the third quarter of 2004. Fully diluted earnings per share for the quarter

Bristol-Myers Squibb Appoints Dr. Elliott Sigal Chief Scientific Officer and President of The Pharmaceutical Research Institute

Thu, 28 Oct 2004 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced the appointment of Elliott Sigal, M.D., Ph.D., to chief scientific officer and president of the company's Pharmaceutical

Bristol-Myers Squibb Mourns the Loss of James B.D. Palmer, F.R.C.P., Chief Scientific Officer and President of the Pharmaceutical Research Institute

Tue, 26 Oct 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the company's respected and beloved chief scientific officer, James B.D. Palmer, died earlier this morning at the age of 51.

Bristol-Myers Squibb to Announce Third Quarter Earnings on October 29, 2004

Mon, 25 Oct 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce 2004 third quarter earnings on Friday, October 29. During a conference call on that day at 10:30 a.m. (ET), financial information will

Elliott Sigal Named Acting President of Bristol-Myers Squibb Pharmaceutical Research Institute

Fri, 22 Oct 2004 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that Elliott Sigal, M.D., Ph.D., senior vice president, Global Clinical and Pharmaceutical Development, will serve as acting

Phase III Clinical Trial Results of Investigational Biologic Abatacept Demonstrated Clinical Activity in Patients With Rheumatoid Arthritis

Mon, 18 Oct 2004 12:00:00 UT

SAN ANTONIO--(BUSINESS WIRE)--According to the results of two phase III clinical trials to be presented this week at the annual meeting of the American College of Rheumatology (ACR), the investigational biologic

ImClone Systems and Bristol-Myers Squibb Provide Erbitux -Cetuximab- Non-Small Cell Lung Cancer Clinical Development Update

Thu, 7 Oct 2004 17:09:00 UT

NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--Oct. 7, 2004--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb (NYSE: BMY) announced today the

Expecta(TM) LIPIL(R) DHA Supplement Now Available For Pregnant and Nursing Women

Wed, 6 Oct 2004 12:00:00 UT

EVANSVILLE, Ind.--(BUSINESS WIRE)--Mead Johnson Nutritionals announced today that it will introduce Expecta LIPIL DHA supplement softgel capsules. Expecta LIPIL is the only non-prescription, non-fish DHA

Bristol-Myers Squibb Submits Applications in U.S. and Europe to Market Entecavir, an Investigational Antiviral Treatment For Chronic Hepatitis B Infection

Mon, 4 Oct 2004 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral

Parents Can Start Saving for Their Children's Education When Purchasing Enfamil(R) Formulas

Tue, 28 Sep 2004 12:00:00 UT

EVANSVILLE, Ind.--(BUSINESS WIRE)--Parents who buy Enfamil formulas can now have 1 percent of their purchase price of qualified products set aside for their children's college education. This savings opportunity is

Bristol-Myers Squibb Tour of Hope(TM) Team, Lance Armstrong to Embark on Cross-Country Cycling Journey from Los Angeles

Wed, 22 Sep 2004 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--The Bristol-Myers Squibb Tour of Hope(TM) Team will begin an eight-day, cross-country bike ride from the City of Hope Cancer Center, Los Angeles, on Thursday, Sept. 30. Cancer survivor

Bristol-Myers Squibb Announces Dividend

Tue, 14 Sep 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE: BMY) today declared a quarterly dividend of twenty-eight cents ($.28) per share on the $.10 par value Common Stock of the

New Long-Term Data Provide Guidance on the Use of Sustiva(R) (Efavirenz) in HIV-Treatment-Naive Patients

Thu, 26 Aug 2004 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that SUSTIVA(R) (efavirenz) has received approval from the U.S. Food and Drug Administration (FDA) to include new long-term

Bristol-Myers Squibb Statement on SEC Settlement

Wed, 4 Aug 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb ("BMS") confirmed today that it has reached a final settlement with the United States Securities and Exchange Commission (SEC), concluding an investigation concerning

Bristol-Myers Squibb Company Extends Exchange Offer on 4.00% Senior Notes

Mon, 2 Aug 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it is extending the expiration date of its offer to exchange (the "Exchange Offer") $1,000 principal amount of its 4.00% Senior

Bristol-Myers Squibb to Settle Securities Class Action Litigation

Fri, 30 Jul 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has reached an agreement to settle its securities class action lawsuit, in re BMS Securities Litigation, Master File, No.

Bristol-Myers Squibb Announces Second Quarter and Six Months Sales and Earnings for 2004

Thu, 29 Jul 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported net earnings of $527 million on sales of $5.4 billion for the second quarter of 2004. Fully diluted earnings per share for the quarter

Bristol-Myers Squibb to Announce 2004 2nd Quarter Earnings on July 29, 2004

Thu, 22 Jul 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce 2004 second quarter earnings on Thursday, July 29. During a conference call on that day at 10:30 a.m. Eastern time, financial

REYATAZ(R) (atazanavir sulfate) Granted Approval For Use With Low-Dose Ritonavir in Treatment-Experienced HIV-Infected Patients

Wed, 14 Jul 2004 12:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that REYATAZ(R) (atazanavir sulfate) has received approval from the U.S. Food and Drug Administration (FDA) to include new

New Mali Center Joins Five Other Novel HIV/AIDS Community-Based Treatment Support Programs

Mon, 12 Jul 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's (NYSE: BMY) real world field test of how HIV/AIDS treatment can

Bristol-Myers Squibb Announces Expected Increases In Legal Reserves Of $400 Million

Mon, 28 Jun 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it expects to increase its reserves for liabilities related to previously disclosed legal matters by approximately $400 million.

Bristol-Myers Squibb Announces Dividend

Tue, 8 Jun 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE: BMY) today declared a quarterly dividend of twenty-eight cents ($.28) per share on the $.10 par value Common Stock of the

ABILIFY(R) (aripiprazole) Approved For Marketing in Europe for the Treatment of Schizophrenia

Mon, 7 Jun 2004 12:00:00 UT

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced that the European Commission has granted marketing authorization for ABILIFY(R)

Bristol-Myers Squibb Tour of Hope(TM) Announces 20 Cancer Survivors, Loved Ones and Experts to Join Lance Armstrong in Raising Awareness of Cancer Clinical Trials

Tue, 1 Jun 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Twenty cyclists have been selected by cancer community leaders to join cancer survivor and five-time Tour de France champion Lance Armstrong in the Bristol-Myers Squibb Tour of Hope(TM).

Bristol-Myers Squibb and Solvay Pharmaceuticals in Development and Commercialization Agreement Involving Novel Obesity Compound

Mon, 17 May 2004 12:00:00 UT

NEW YORK & BRUSSELS, Belgium--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Solvay Pharmaceuticals today announced that the companies have entered into a worldwide agreement for the Solvay compound

Lesotho Launches Its Public Sector ARV Learning Center With $3.9 Million In Support From Bristol-Myers Squibb's Secure the Future Program

Fri, 7 May 2004 12:00:00 UT

LESOTHO, Africa--(BUSINESS WIRE)--SECURE THE FUTURE, an HIV/AIDS program of The Bristol-Myers Squibb Company (NYSE: BMY), marked its fifth anniversary with a launch of the Lesotho, Africa, site of its community- based

Clinical Study Shows Intramuscular Administration of Aripiprazole (ABILIFY(R)) Significantly Improves Acute Agitation in Patients With Schizophrenia

Wed, 5 May 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Patients with schizophrenia, schizoaffective and schizophreniform disorders who received treatment with intramuscular (IM) administration of aripiprazole (ABILIFY(R)) showed significant

New Data and Analyses Demonstrate ABILIFY(R) (Aripiprazole) Effective at Treating Patients With Acute Manic and Mixed Episodes of Bipolar Disorder

Wed, 5 May 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--ABILIFY(R) (aripiprazole) was demonstrated to be effective in treating acute manic and mixed episodes in patients with bipolar disorder, and maintenance of effect for up to 26 weeks was

Bristol-Myers Squibb Announces First Quarter Sales and Earnings For 2004

Wed, 28 Apr 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported net earnings of $964 million on sales of $5.2 billion for the first quarter of 2004. Fully diluted earnings per share for the quarter

Bristol-Myers Squibb and Merck Announce Global Development And Commercialization Alliance for Muraglitazar, a Novel Compound For Diabetes

Wed, 28 Apr 2004 12:00:00 UT

NEW YORK & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Merck & Co., Inc. (NYSE: MRK) today announced that they have entered into a global collaborative agreement for

Bristol-Myers Squibb Statement on Paraplatin Settlement

Tue, 27 Apr 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) reported the settlement of patent infringement litigation by it and patent holder Research Corporation Technologies Inc. against Pharmachemie Group (a

Bristol-Myers Squibb and Metrika Announce Exclusive U.S. Supply Agreement for A1cNow(R) Diabetes Monitor

Wed, 21 Apr 2004 12:00:00 UT

PRINCETON, N.J. & SUNNYVALE, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and privately held Metrika Inc. today announced that the companies have entered into an agreement to distribute and sell

Bristol-Myers Squibb to Announce 2004 First Quarter Earnings on April 28, 2004

Wed, 21 Apr 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce 2004 first quarter earnings on Wednesday, April 28. During a conference call on that day at 10:30 a.m. (ET), financial information will

Bristol-Myers Squibb and Pierre Fabre Medicament S.A. Enter Into Agreement to Develop and Commercialize Oncology Treatment Javlor(R) (vinflunine)

Tue, 20 Apr 2004 12:00:00 UT

PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pierre Fabre Medicament S.A., a privately held pharmaceutical company headquartered in France, today announced that they have

Cutting Edge HIV/AIDS Monitoring Research Funded by Bristol-Myers Squibb Leads to Significant Cost Savings for African Nations

Thu, 15 Apr 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--The cost of HIV/AIDS monitoring has long been a barrier to successful treatment in Africa. Now, research funded by SECURE THE FUTURE(R), an HIV/AIDS philanthropic initiative funded by the

Bristol-Myers Squibb Announces Acquisition of Acordis Speciality Fibres Business

Tue, 6 Apr 2004 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the company has completed the acquisition of Acordis Speciality Fibres from Acordis, a multinational group of businesses. This

Bristol-Myers Squibb Statement Regarding Paraplatin Pediatric Submission and Federal Appeals Court Reversal on Patent

Wed, 31 Mar 2004 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) reported today that it has submitted to the Food and Drug Administration (FDA) data from two clinical studies evaluating the potential health benefits

Lance Armstrong and Cancer Community Seek Cyclists to Participate in 2004 Bristol-Myers Squibb Tour of Hope(TM)

Wed, 17 Mar 2004 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Cancer survivor and five-time Tour de France champion Lance Armstrong and Bristol-Myers Squibb Company announced today that they will partner again this year to inspire and invigorate

New Study Demonstrates the Benefits of Intensive Statin Therapy In Patients Hospitalized with Acute Coronary Syndrome

Mon, 8 Mar 2004 13:00:00 UT

PRINCETON, N.J.--(BUSINESS WIRE)--Results from a new study demonstrate the benefit of initiating intensive cholesterol-lowering therapy within 10 days in people hospitalized with an acute coronary syndrome. The TIMI 22

Bristol-Myers Squibb Announces Dividend

Tue, 2 Mar 2004 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE: BMY) today declared a quarterly dividend of twenty-eight cents ($.28) per share on the $.10 par value Common Stock of the

ERBITUX(TM) (Cetuximab) Receives FDA Approval to Treat Irinotecan Refractory Or Intolerant Metastatic Colorectal Cancer

Thu, 12 Feb 2004 13:00:00 UT

NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--ImClone Systems Incorporated (Nasdaq: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved

Women In Government Announces Partnership With Bristol-Myers Squibb Foundation to Convene First Ever Summit of State Offices of Women's Health

Tue, 10 Feb 2004 13:00:00 UT

WASHINGTON--(BUSINESS WIRE)--Women In Government, a non-profit, bipartisan educational association for elected women in state government, announced today a two-year plan to hold educational summits, the first of their

Bristol-Myers Squibb Announces Fourth Quarter And Twelve Months Sales and Earnings for 2003

Thu, 29 Jan 2004 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported net earnings of $429 million on sales of $5.6 billion for the fourth quarter of 2003. Fully diluted earnings per share for the quarter

$4.6 Million in 'Freedom to Discover' Grants Awarded To 10 Leading Medical Research Institutions

Tue, 27 Jan 2004 13:00:00 UT

LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Research to combat AIDS, drug addiction, diabetes, cancer and other diseases will be funded through $4.6 million in philanthropic grants from Bristol-Myers Squibb, Peter R. Dolan,

ImClone Systems Incorporated and Bristol-Myers Squibb File New Drug Submission with Health Canada for Use of ERBITUX--cetuximab--for Treatment of EGFR-Expressing Irinotecan-Refractory Metastatic Colorectal Cancer

Mon, 24 Nov 2003 11:30:00 UT

NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--Nov. 24, 2003--ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced

ImClone Systems and Bristol-Myers Squibb Announce Acceptance of Erbitux -Cetuximab- Biologics License Application for Review by the U.S. Food and Drug Administration

Fri, 10 Oct 2003 23:32:00 UT

NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--Oct. 10, 2003--ImClone Systems Incorporated (Nasdaq: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced